Claudin-1 is the direct target of RUNX3 in gastric epithelial cells by CHANG TI LING
  
CLAUDIN-1 IS THE DIRECT TARGET OF RUNX3 IN 






















CLAUDIN-1 IS THE DIRECT TARGET OF RUNX3 IN 







CHANG TI LING 






A THESIS SUBMITTED  
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF MEDICINE 






My gratitude goes to both my supervisors, Prof. Yoshiaki Ito and A/P Kosei Ito for 
their patient guidance and discussions throughout my PhD study. I thank them for 
critically reviewing my work during our progress report sessions, as well as their 
useful advice for improvements.  
 
I would also like to specially thank my ex-supervisor, A/P Evelyn Koay, the Director 
of Molecular Diagnosis Centre, NUH for her constant support and encouragement. 
Without her nurturing and many opportunities given, I will not be where I am today.   
 
My gratitude also goes to the Singapore Millennium Foundation for providing me the 
SMF scholarship during the first three years of my PhD project and the sponsored trip 
to the Gordon Research Conferences, as well as to the NUS for my final year of 
scholarship. I also thank the Oncology Research Institute common grant for 
supporting my PhD work throughout.  
 
My sincere appreciation also goes to all my fellow colleagues and friends at ORI 
(Tomoko, Tada-san, TK, Angela, KumChew, PeiYi, FenYi, BeeKeow, Michelle, 
Kathryn, Dr. LihWen, Dr. Vidya, Baidah, Diyanah, Erna, Judy, Mei Xian and 
ShenKiat) and IMCB RUNX group (Cecilia, Dominic, Anthony, Dr. Osato, 
YungKiang, Eunice, Ida, Yano and Ken-ichi) for their kind assistance and 
constructive advice along my PhD journey. I thank them for their friendship. Many 
thanks also to the ORI administrative team, Selena Gan, Deborah, Ivy, Alexis and 
Siew Hong for their kind help.  
 
Last but not least, I would like to specially thank my beloved husband, Andy Yip for 
his loving care, trust, sacrifice and constant moral support and encouragement to 
make my PhD journey a possible one. I thank God for our baby Jasper who brought 
much joy and hope towards the end of my PhD project. Endless gratitude also goes to 
ii 
 
my beloved parents, family members, cell members (Doris, BoonLay & FeeYoon, 
Selena & Willie, PohChoo, Anna & Charles, SiorPeng & ChekLeong, Winnie & 
ShenKong) and friends (Hazel, Eileen, HueyFen, HongLing, Maisy, Tony and 





























TABLE OF CONTENTS 
     
                Page 
ACKNOWLEDGEMENTS           i                                                         
TABLE OF CONTENTS        iii 
SUMMARY          vii 
LIST OF TABLES         ix 
LIST OF FIGURES         x 
LIST OF ABBREVATIONS       xii 
 
CHAPTER 1  OBJECTIVE       1 
CHAPTER 2  INTRODUCTION      2 
 
2.1  Gastric Cancer       2 
2.1.1 Genetics of Gastric Cancer     3 
2.2  RUNX Protein Family      5 
  2.2.1 Nomenclature of RUNX     7  
  2.2.2 Evolutionary Conservation of RUNX    9 
2.3  Role of RUNX Protein Family     9 
2.3.1 RUNX1       9 
2.3.2 RUNX2       11 
2.3.3 RUNX3       11 
2.4.  RUNX and TGF-β Tumor Suppressor Pathway   12 
2.5  RUNX3 and Gastric Cancer      15 
2.5.1 Tumor Suppressive Mechanism of RUNX3 in  19  
Gastric Cancer  
2.6  Tight junction (TJ) Protein Family     21 
2.7  Claudin Superfamily       23 
2.7.1    Emergence of Claudin Superfamily    23 
2.7.2 Evolution of Claudin Genes Family    24   
iv 
 
2.7.3 Claudin Protein Structure and Functions   25 
2.8  Claudin and Cancer       29 
2.8.1 Claudin and Gastric Cancer     30 
2.9  Crosstalk of TJ Components with Signaling Pathways  31 
2.10  TJ, AJ and Mechanism in Tumor Metastasis    33 
      
 
CHAPTER 3  MATERIALS AND METHODS 
 
3.1  MATERIALS        39 
3.1.1 Primers       39 
3.1.2 Oligonucleotide probes for EMSA    42 
3.1.3 Commercial kit      43 
3.1.4 Antibodies       44 
3.1.5 General Buffer Preparation     45 
3.2  METHODS 
3.2.1 Establishment of Gastric Epithelial Cell Lines  49 
  3.2.2 Cell Lines and Cell Culture     51 
3.2.2.1 Treatment of Cells by TGF-β1   52 
3.2.3 Semiquantitative RT-PCR, Quantitative RT-PCR  52   
3.2.4 Protein Isolation       53 
3.2.5 SDS-PAGE and Western Blot Analysis   54 
3.2.6 Promoter Assay      55 
3.2.6.1 Cloning of  hclaudin-1 Promoter   55 
3.2.6.2 Site-Directed Mutagenesis    56 
3.2.6.3 Dual-Luciferase Reporter Assay   58 
3.2.7 Generation of Stable Cell Line    60 
3.2.7.1 Plasmids and Stable Cell Line   60 
3.2.7.2 Stable Transfection and Stable Cloning  61 
v 
 
3.2.8 Xenografts in Nude Mice     62 
3.2.9 Collection and Processing of Mouse and Human  64 
Tissue Samples 
3.2.9.1 Fixing, Processing and Embedding of Mouse  64 
Stomach 
3.2.9.2 Human Gastric Cancer Specimens    64 
3.2.10 Microscopy Technique     65 
3.2.10.1 Immunocytochemistry (IF)    65
  3.2.10.2 Immunohistochemistry (IHC)  
 66 
3.2.11 Electrophoresis Mobility Shift Assay (EMSA)  67  
3.2.12 Chromation Immunoprecipitation (ChIP)    69 
 
CHAPTER 4  RESULTS AND DISCUSSIONS 
 
4.1  Results 
4.1.1 Expression of TJ Proteins in Mouse    71  
Gastric Epithelial Cells  
4.1.2 TJ Proteins and TGF-β Pathway    73 
4.1.3 RUNX3 and claudin-1 in TGF- β Pathway   74 
4.1.4 claudin-1 Expression in Mouse Gastric Epithelial Cells 77 
4.1.5 claudin-1 Promoter Assay     79 
4.1.6 Electrophoresis Mobility Shift Assay (EMSA)  84 
4.1.7 Chromatin Immunoprecipitation (ChIP)    86
  
4.1.8 Nude Mice Assay      88 
4.1.8.1 Restoration of claudin-1 Expression and Its Tumor  88 
Suppressive Effect  




4.1.9 Claudin-1 and RUNX3 Expression in Human Gastric  92 
Cancer Samples 
4.2  Discussions           99 
CHAPTER 5  CONCLUSIONS AND FUTURE PERSPECTIVE           
104 
REFERENCES         106 
APPENDICES 
 
1 Genomic Structure of Runx3, Structure of The Targeting    125 
Vector For Homologous Recombination, and The Gene  
Structure of The Targeted Locus  
2 Full Length Sequence of hclaudin-1 Promoter (1530 bp)   126 
3 pGL3 Vector for Cloning of Promoter     127 
4 pRLSV40 Vector        128 
5 Human RUNX3 cDNA       129 
6 Full Length Sequence of mclaudin-1 Open Reading Frame (636 bp) 130 
















The genes controlling cell-cell contact and cellular polarity are known to be heavily 
involved in cancer progression. Tumorigenic mouse GIF cells isolated from Runx3-/-  
gastric epithelium attached weakly to each other and did not form glandular structures 
on collagen gels as previously reported, suggesting that cellular polarity could not be 
established in the Runx3-/-  cells. In a search for RUNX3 target genes functioning in 
gastric carcinogenesis, claudin-1, a gene from the tight junction protein family which 
functions in cell-cell contact and cellular polarity was found to be expressed at high 
level in Runx3+/+ mouse gastric epithelial cells, but at very low level in Runx3-/- ones.  
In human gastric cancer cell line, SNU16, RUNX3 is expressed in the 
cytoplasm in an inactive form and, upon treatment of cells by TGF-β, RUNX3 
translocates into the nucleus and functions as a tumor suppressor. In SNU16, claudin-
1 is expressed after the treatment of cells with TGF-β. The TGF-β-dependent 
expression of claudin-1, however, was not observed in RUNX3-knocked-down 
SNU16 cells. Furthermore, hclaudin-1 promoter activity was dose-dependently up-
regulated by expression of RUNX3. Chromatin immunoprecipitation assay showed 
that RUNX3 is bound to the cognate RUNX3 binding site in the promoter region of 
hclaudin-1.  
SNU16 cells express claudin-1 and knock-down of claudin-1 expression 
enhanced tumorigenicity in nude mice. Furthermore, the tumorigenicity of Runx3-/- 
GIF clones stably expressing claudin-1 was significantly less than parental cell lines. 
viii 
 
Altogether, these results showed that claudin-1 has a tumor suppressor activity in 
gastric epithelial cells. Consistent with these observations, expression of claudin-1 
and RUNX3 expression were found to be correlated in the human gastric cancer 
specimens. 
 For the first time, claudin-1 was identified as a novel downstream target of 
RUNX3 in the TGF-β pathway. Strong evidence showed that RUNX3 transcriptionally 
regulates the expression of claudin-1. Since claudin-1 exhibits tumor suppressive 
activity, a part of tumor suppressor activity of RUNX3 is likely to be mediated by 
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The aim of the study is to understand the full potential of RUNX3 as a tumor 
suppressor. Since RUNX3 is a transcription factor, the identification of the target 
genes that are induced or suppressed by RUNX3 should provide important insights 
into the molecular mechanism behind its tumor suppressor activity. Since RUNX3 is a 
nuclear effecter of TGF-β pathway and  TGF-β pathway is considered to be a tumor 
suppressor pathway, it is important to identify TGF-β dependent, RUNX3 mediated 
target genes.  
Based on a previous observation that the loss of RUNX3 affects cell-cell 
contact and polarity, I would like to examine whether RUNX3 regulates genes involve 
in this function and its possible link to gastric carcinogenesis. Previously, it was 
observed that claudin-1, a member of the tight junction protein family exhibited a 
similar knockout phenotype as those of Runx3-/-. As RUNX3 functions as a tumor 
suppressor under the TGF-β pathway, it would be feasible to observe if tight junction 
genes are regulated under this pathway in the gastric epithelial cells, which is an area 
yet to be examined. Findings of possible connections between RUNX3 and tight 
junction proteins in the gastric system may enable the development of useful 










2.1 Gastric Cancer 
 
  
With the steady decline in the incidence of gastric cancer worldwide, it has become 
the fourth most common cancer, after cancers of the lung, breast, and colorectal. This 
is in comparison to its ranking as the second most common cancer worldwide in the 
past (1). However, gastric cancer remains a major public health problem as it remains 
the second most common type of fatal cancer worldwide (1, 2). There has been little 
improvement in survival as gastric cancer is too often diagnosed at an advanced stage, 
despite the extensive diagnostic and therapeutic investigations of gastric cancer.  
Although gastric cancer frequencies have been clearly linked to environmental 
factors, such as Helicobacter pylori infection and diet, the genetic basis for gastric 
cancer development is still largely unclear. It is evident that transformation of a 
normal epithelial cell to a malignant cell is a result from the accumulation of several 
gene abnormalities which involves multiple steps. Correa postulated a model 
involving histomorphological changes that leads to gastric cancer (3). In this model, 
development of chronic gastritis, atrophy, intestinal metaplasia and eventually 
dysplasia results in gastric cancer. However, this model is still open to debate as it 
remains unclear whether these changes follow each other step by step, or whether 




2.1.1 Genetics of Gastric Cancer 
 
Over the years, various genetic and epigenetic alterations have been associated with 
the development and progression of gastric cancer. These include microsatellite 
instability (MSI), reactivation of telomerase, inactivation of tumor suppressor genes 
and activation of oncogenes.   
Due to DNA mismatch repair deficiency, replication errors in simple 
repetitive microsatellite sequences may occur which is defined as MSI. MSI can be 
classified as high-frequency (MSI-H), low-frequency (MSI-L), or stable (MSS). MSI 
has been recognized as one of the earliest changes in carcinogenesis, resulting in 
genomic instability. It was discovered that gastric cancer cases with MSI-H often 
show hypermethylation of CpG islands in the promoter region of the hMlh1 gene 
which is associated with decreased hMlh1 protein expression. This indicates that 
epigenetic inactivation of hMlh1 due to promoter methylation could be the underlying 
cause of MSI (5, 6). A subset of gastric cancers including gastric tumors was found to 
harbor MSI (7, 8). Various genes involved in the regulation of cell-cycle progression 
and apoptotic signaling that have been found to be specifically altered in gastric 
cancer displaying MSI include BAX, hMSH3, hMSH6, E2F-4, TGF-β receptor II, and 
insulin-like growth factor receptor II (7). In view of this, MSI has been suggested as a 




Tumor suppressor genes and oncogenes play a general role in regulating the 
developmental and differentiation processes. Deregulation of these genes enables the 
development of cancer. Inactivation of tumor suppressor genes is frequently 
discovered in gastric carcinogenesis (10). It is known that at least two independent 
‘hits’ are required to fully inactivate a tumor suppressor. The attention in cancer 
research has typically been on two of the mechanisms that inactivate tumor 
suppressors, namely loss of heterozygosity (LOH) or homozygous deletion. LOH in 
chromosomal loci such as 1p, 2q, 4p, 5q, 6p, 7q, 11q, 12q, 14q, 17p, 18q and 21q 
have been discovered in differentiated type of gastric cancer (11-14). However, it 
remained unclear which are the genes that are specifically involved in gastric 
carcinogenesis. It was then found that DNA methylation is also a powerful 
mechanism that suppresses gene transcription, which represents an alternative 
mechanism of tumor suppressor inactivation in cancer. Genes that are inactivated by 
DNA methylation include RB, the von Hippel-Lindau gene (VHL), CDKN2A 
(p16INK4A), CDKN2B (p15INK4B), E-cadherin (E-cad), hMLH1, APC, RASSF1 and 
caspase-8 (15-17).  
 The group of activated oncogenes consists primarily of various growth factors 
and growth factor receptors. c-met, a proto-oncogene which encodes a tyrosine kinase 
receptor for the hepatocyte growth factor, was overexpressed in 50% of diffuse and 
intestinal-type of gastric cancers. Tumors overexpressing c-met also display increased 
invasiveness and are poorly differentiated (18). The overexpression of c-erB2 (HER-
2/neu) gene, a proto-oncogene and a transmembrane tyrosine kinase receptor was also 
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found to associate with approximately one-fourth of all gastrointestinal tract 
malignancies (19), and has been implicated as a potential marker for the prognosis in 
gastric cancers (20). Oncogenes, such as cyclin E and and c-myc were also discovered 
to be amplified and overexpressed in gastric carcinoma (21, 22). 
 Though numerous genetic abnormalities associated with gastric cancer have 
been described, they were either associated with a limited number of cases or were 
still poorly understood. The molecular mechanisms underlying the pathogenesis of 
gastric cancer have only been characterized recently with the discovery of RUNX3 
and its role in gastric carcinogenesis. The reason why RUNX3 was not identified as a 
tumor suppressor earlier could be because this gene is inactivated mainly by 
epigenetic modification and genetic alteration of both alleles is very rare. RUNX3 
appears to be a new addition to the list of genes that are inactivated by DNA 
methylation. Since its discovery as a strong candidate tumor suppressor in gastric 
carcinogenesis (23), the underlying mechanisms of RUNX3 regulation and its 
downstream target genes in gastric carcinogenesis became the subject of active 
investigations.  
 
2.2      RUNX Protein Family 
 
RUNX genes encode the α subunits called the polyomavirus enhancer-binding protein 
2 (PEBP2)α/core binding factor (CBF)α of the Runt domain transcription factors. The 
α subunit heterodimerizes with the β subunits (PEBP2β/CBFβ) to form the 
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heterodimeric transcription factor, initially discovered as the PEBP2, or the CBF, 
which interacts with the enhancer core of Moloney murine leukemia virus. RUNX 
proteins alone are unstable, as they are subjected to ubiquitination followed by 
proteolytic degradation by proteasome enzymes (24). Heterodimerization with the β 
subunit prevents ubiquitination, thus stabilizing RUNX proteins (Figure 2.1).  
However, RUNX heterodimers are relatively weakly acting transcriptional 
regulators. Associations with transcriptional co-activators, such as MYB, ETS, and 
p300/CBP, or co-repressors such as TLE1 and mSin3A however can induce the 
potency of its transcriptional function (25). Due to the low expression level of RUNX 
proteins, subcellular localization of RUNX proteins has been studied largely using 
exogenously expressed RUNX proteins in fibroblasts and leukemic cells. 
Immunocytochemistry shows that RUNX proteins are localized in the nucleus, 
whereas exogenously expressed PEBP2β/CBFβ is in the cytoplasm.  
To date, three RUNX genes, namely RUNX1, RUNX2 and RUNX3 have been 
identified in mammals, whereby all three genes contain a conserved region, termed 
the Runt domain (26). By comparing between the mouse PEBP2αA1 (Runx2), mouse 
PEBP2αB1 (Runx1), and human PEBP2αC1 (RUNX3) as well as Drosophila Runt 
proteins, PEBP2αA1 and PEBP2αC1 was found to be 93.8% identical in homology, 
whereas PEBP2αB1 and PEBP2αC1 was 93.0% identical in homology. Besides, all 
three Runt domain proteins also have a C-terminal end containing a unique five 
amino-acid sequence, identified as VWRPY, which is 100% conserved from 
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Drosophila to human (27). This C-terminal part of the RUNX molecule plays a role 









Figure 2.1: Crystal structure of the Runt domain heterodimerized with the 134 
amino-acid region of PEBP2/CBF bound to DNA. [Ref. 23] 
 
 
2.2.1 Nomenclature of RUNX 
 
The runt-domain transcription factors RUNX1, RUNX2 and RUNX3 have previously 
been assigned various designations by different laboratories. The designation acute 
myelogenous leukemia (AML) factors (ie. AML1, AML2 and AML3) was generated 
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based on the genetic studies of leukemia-related chromosomal translocations. Core-
binding factor alpha (CBFA) was initially characterized as sequence specific DNA-
binding proteins that interact with the enhancers of retroviruses. PEBP2 was named 
after the murine cDNAs polyoma enhancer-binding proteins. Other aliases, such as 
nuclear matrix protein 2 (NMP2), osteoblast-specific complex (OBSC) and 
osteoblast-specific factor 2 (OSF2) were also generated. In November 1999, the 
Nomenclature Committee of the Human Genome Organization (HUGO) adopted the 
use of the term ‘RUNX’ to refer to the genes encoding the runt-related proteins, also 
an abbreviation for the term ‘runt-related protein’. The mammalian RUNX proteins 
and their synonyms as well as their locus are as listed in Table 2.1. The order of the 
numbers was given according to the order in which the knock-outs for each of the 
mouse Runx genes were published (Runx1/Aml1 in 1996 (30, 31), Runx2/Cbfa1 in 
1997 (32, 33) and Runx3/Pebp2αC in 2002 (23).    
 
Table 2.1: The mammalian RUNX genes synonyms and their locus  
                  (Adapted from Oncogene 2004; 23:4209-10) 
RUNX1 CBFA2 AML1  PEBP2alphaB  21q22 
RUNX2 CBFA1 AML3  PEBP2alphaA  6p21 






2.2.2 Evolutionary Conservation of RUNX   
 
Besides the three RUNX genes in mammals, four genes have been reported in D. 
melanogaster (34), (35), (36), one in sea urchin (37), one in Xenopus (38), four in 
zebra fish (39), (40), (41), and one in C. elegens (42). RUNX genes also appear to be 
conserved throughout in metazoa, the most primitive organism described so far, with 
the findings of RUNX homologs in basal metazoans such as starlet sea anemone 
(Nematostella vectensis) (43) and sponge (Oscarella carmela) (44). This shows that 
RUNX genes were highly conserved throughout the evolution, and very likely to play 
an important role in the early metazoan development and evolution. Like their 
counterparts in D. melanogaster and C. elegans, mammalian RUNX family 
transcription factors also play important roles in cell fate determination during 
development. As reported for Runx1 (30), Runx2 (32, 33) and Runx3 (23), genetic 
ablation of all these genes have profound effects on development processes.  
 
2.3 Role of RUNX Protein Family 
  
2.3.1 RUNX1   
 
RUNX1 is known to play a critical role in hematopoietic development and is 
genetically altered in leukemia. RUNX1 is the most frequent target of chromosomal 
translocations associated with human leukemia, with the TEL-AML t(12;21) fusion 
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accounting for 20% of acute lymphoblastic leukemia (ALL) cases and the AML-ETO 
t(8;21) fusion accounting for 12% of acute myeloid leukemias (AML) (45). 
Heterozygous loss-of-function mutations which cause haploinsufficiency of RUNX1 
are associated with familial platelet disorder with predisposition to acute myeloid 
leukemia (FPD-AML) (46). This supported the hypothetical function of RUNX1 as 
tumor suppressor for AML. Besides, sporadic heterozygous mutations and point 
mutations of RUNX1 are also leukemogenic (47, 48). Its association with several 
autoimmune diseases, namely, systemic lupus erythematosus, rheumatoid arthritis 
and psoriasis has also been reported (49), (50).  
 In mouse model, genetic ablation of Runx1 results in embryonic lethality and 
a complete lack of fetal liver hematopoiesis (30), (31). Runx1 is also essential for the 
generation of hematopoietic stem cells (HSCs) (51, 52). Runx1-deficient hematogenic 
endothelial cells are incapable of producing hematopoietic stem cells (HSCs), 
suppo rting its role in the initiation of the hematopoietic system. However, Runx1 is 
not necessary for the maintenance of HSCs in the adult stage or expansion of 
HSC/progenitor cells (HSC/Ps). Instead, lack of Runx1 induces myeloproliferative 
disease and T-cell lymphoma. It was thus suggested that Runx1 plays a role as a 









RUNX2 is essential in osteogenesis. In human and mice, deletions, insertions or 
mutations that inactivates one allele of the RUNX2 gene causes the autosomal 
dominant bone disorder, called cleidocranial dysplasia (33, 53, 54). Runx2 gene 
product is necessary for osteoblast differentiation and bone ossification as Runx2-
knockout mice display complete bone loss, whereas Runx2 heterozygous mice 
displayed hypoplasia of the clavicle and delayed development of membranous bones 
which were all typical features of cleidocranial dysplasia (32, 33). 2Interestingly 
however, Runx2 has also been described as an oncogene whereby the overexpression 
of Runx2 pertubates T cell development in lymphomagenesis by its cooperation with 
c-myc (55). However, the oncogenic property of Runx2 is something yet to be fully 




As compared to RUNX1 and RUNX2, RUNX3 is involved in more diverse biological 
pathways. Besides playing a role in gastric carcinogenesis as shown by targeted 
deletion of Runx3 in mice (23), its role in CD8-lineage T-cells development (56, 57) 
and in dendritic cells (58) have also been reported. Besides, absence of Runx3 also 
affects the biological function of the TrkC-dependent dorsal root ganglion neurons as 
reported by Inoue et al. (2002) (59) and Levanon et al. (2002) (60). Possible 
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involvement of RUNX3 in the cancers of the lung, colon, pancreas, liver, prostate, bile 
duct, breast, larynx, esophagus, endometrium, uterine cervix and testicular yolk sac 
was also reported (61-75). Since RUNX3 is involved in so many different cancer 
types, it may also be playing critical roles in different aspects of carcinogenesis.  
 
2.4 RUNX and TGF-β Tumor Suppressor Pathway 
 
Transforming growth factor-β (TGF-β) is a family of multifunctional cytokines that 
regulate the growth, differentiation, apoptosis and matrix accumulation of wide 
varieties of cells (76). It is a member of the TGF-β superfamily which includes bone 
morphogenetic proteins (BMPs), activins, Nodal, myostatin, and anti-Mullerian 
hormone (AMH). TGF-β, activin, Nodal and myostatin activates the TGF-β-like 
signals, whereas BMPs and AMH activates BMP-like signals.  
TGF-β is essential in many development and physiological processes. It acts 
as a potent growth inhibitor of most cell types, such as the epithelial cells, endothelial 
cells, hematopoietic cells, and lymphocytes. Abnormalities in the TGF-β receptor 
affect downstream signal transduction pathways involved in the control of cell growth 
and differentiation, which often results in tumor progression, thus is regarded as a 
tumor suppressor pathway (77-79). Heterozygously disrupted TGF-β1 displayed 
increased hepatocyte proliferation and decreased apoptosis in liver and lung, which 
induced liver and lung cancer when challenged with chemical carcinogen (80). TGF-
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β1 knockout mice also show hyperplasia in the epithelial cells of glandular stomach 
(81).  
It is interesting to note that some functions of the TGF-β superfamily 
cytokines are similar to those of RUNX proteins. For example, TGF-β acts on B 
lymphocytes and induces synthesis of IgA, and Runx1 exhibits a similar effect. BMPs 
induce bone formation, which is similar to the function of Runx2. TGF-β also 
regulates growth and apoptosis of gastric epithelial cells, which are also regulated by 
Runx3. True enough, Runt domain transcription factors were found to be important 
targets of TGF-β superfamily signaling. Smad2 and Smad3 which acts as signal 
transducers in the TGF-β signaling pathway were shown to interact with RUNX1, 
RUNX2 and RUNX3 in vitro (82). Physiologically, endogenous RUNX2 also 
interacts with endogenous Smad3 in 10T1/2 and ROS17/2.8 cells (83).   
In the TGF-β signaling pathway, members of the TGF-β superfamily bind to 
two distinct transmembrane receptors, the type I, which is a threonine kinase receptor, 
and type II, which is a serine kinase receptor (84). Upon binding of their 
corresponding ligand to type I and type II receptors, type II receptor kinases 
transphosphorylate the juxtamembrane domains of the type I receptor kinases, 
forming a heterotetramers. This activated form of receptor then phosphorylates the 
receptor-regulated Smads (R-Smads), namely Smad2 and Smad3, which will then 
form hetero-oligomeric complexes with the common-partner Smad (Co-Smads), 
Smad4. The R-Smad-Co-Smad complexes then translocate into the nucleus and binds 
to transcription factors to regulate the transcription of target genes. These 
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transcription factors would act along with other transcription factors, co-activators 
and co-repressors to regulate various genes upon stimulation by members of the TGF-
















Figure 2.2: The TGF-β tumor suppressor pathway. Mutations in the genes encoding 
TGF-β type I and type II, Smad2/3 and Smad4 are linked to various cancers as 
indicated. The transcriptional co-activator p300 is also mutated in several cancers. 





Both TGF-β signaling components and RUNX establish a functional 
relationship by working synergistically to regulate the downstream target genes.  
Figure 2.2 shows a schematic diagram of the transcription regulation by RUNX3 
under the TGF-β tumor suppressor pathway. Various cancers linked to mutations in 
the gene encoding TGF-β type I and type II receptors, Smad2/3, Smad4 (DPC4) and 
the transcriptional co-activator p300 were depicted in the diagram (78, 85-87). 
 
2.5 RUNX3 and Gastric Cancer 
 
Identification of Runx3 expressing tissues has been challenging and complicated since 
results generated from different methods of detection were different. Besides, 
temporal and spatial changes of expression also add to the complexity. However, 
Runx3 appears to be expressed ubiquitously in many cell types including epithelial 
cells, mesenchymal cells and blood cells. Expression in peripheral nervous system 
including dorsal root ganglion neurons, epithelial cells in the adult gastrointestinal 
tract and hematopoietic cells are especially prominent (88).    
RUNX3 has been identified as the smallest gene in the family, which span 
about 67kb with six exons. Based on the genomic structure complexity, Bangsow et 
al. (2001) (89) proposed that RUNX3 is the most primitive of the three genes though 
the precise chronology of evolutional diversification of the genes still remains to be 
determined (36). However, it is still interesting to note that Runx3 is involved in the 
development of primitive monosynaptic neurons (59, 60). Both C. elegens and sea 
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urchins also contain one Runx gene, which are expressed in the intestine and foregut 
respectively (42, 90). In mouse, Runx3 is expressed in the gastrointestinal organs of 
the developing embryo and throughout the adulthood of the mouse. RUNX3 function 
in the stomachs of mammals may therefore be evolutionarily conserved.  
In human, RUNX3 is found in locus 1p36, a region that is frequently deleted in 
many type of cancers, and was postulated to contain other important tumor suppressor 
gene(s) (91). Several lines of evidence have demonstrated that RUNX3 is a tumor 
suppressor of gastric cancer (23, 92). Work by Li et al (2002) shows that while Runx3 
knockout mice are born in Mendelian ratios, they die soon after birth, possibly due to 
starvation. The gastric epithelium of Runx3 knockout mice displays hyperplasia due 
to an increase in cell proliferation and a reduced apoptosis rate (23, 93). A reduced 
sensitivity to TGF-β1 was also shown in Runx3 knockout mice, suggesting that 
RUNX3 operates downstream of the TGF-β signaling pathway, which is a well-known 
tumor suppressive pathway. Runx3-/- gastric epithelial cells in a p53-/- background 
are tumorigenic in nude mice, whereas those from Runx3+/+p53-/- mice are not. This 
suggests that Runx3 functions in keeping cell proliferation under control, which is a 
typical feature of a tumor suppressor. 
Studies in mice have implicated the importance of Runx3 in the growth and 
differentiation of mouse gastric epithelial cells (93-95). Observation of the 
Runx3+/+p53-/- and Runx3-/-p53-/- cells using phase contrast microscopy showed 
that both types of cells were relatively homogenous in appearance, and exhibited 
polygonal morphology, a characteristic of epithelial cells (Fig. 2.3A and B). Further 
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examination of the Runx3+/+ and Runx3-/- gastric epithelial cells revealed that when 
cultured between collagen gels, Runx3+/+ cells formed simple columnar epithelia 
with occasional glandular structures. The cells showed polarity with positive staining 
for PAS, which stains mucus localized on the luminal surface, a characteristic of 
mucous neck cells, indicating that they retain the phenotype of relatively 
undifferentiated gastric epithelial cells (Fig. 2.3C) In contrast, Runx3-/- cells attached 
weakly to each other and did not form glandular structures, but piled between 
collagen gels. Some cells were weakly stained with PAS, indicating that they 
synthesized and secreted mucus, but mucus droplets were evenly distributed in their 
cytoplasm, suggesting that cellular polarity could not be established when cells were 
combined with collagen gels (Fig. 2.3D) (95).  
Besides, it was also found that primary gastric cancer specimens express 
significantly lower levels of RUNX3 due to a combination of hemizygous deletion 
and hypermethylation of the RUNX3 promoter region. Of 46 primary human gastric 
cancer specimens, 30% displayed hemizygosity of RUNX3. Intragenic mutation in the 
remaining allele was however very rare. Instead, RUNX3 gene was silenced by DNA 
methylation on the CpG island located in the proximal (P2) promoter region, which 
resulted in reduced RUNX3 level in 45-60% of the primary human gastric tumors 
analyzed, which further rised to nearly 90% among the late stage, representing highly 
metastatic tumors. One incidence of a single point mutation involving a single-
nucleotide transition of arginine 122 to cysteine (R122C) within the conserved Runt 
domain was also discovered in the 119 human tumors investigated. When tested on 
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nude mice, exogenous RUNX3 greatly reduced tumor growth, while the R122C 














Figure 2.3: Characteristic of mouse gastric epithelial cell lines in vitro. Phase 
contrast micrographs of Runx3+/+p53-/- GIF9 cell line (A), and Runx3-/-p53-/- GIF5 
cell line (B) in culture. Light micrographs of Runx3+/+p53-/- GIF9 (C) and Runx3-/-
p53-/- GIF5 cells (D) cultured between collagen gels, and stained with PAS-




In N-methyla-N-nitrosourea (MNU)-treated mice that developed gastric 
cancer, Runx3 was also inactivated by DNA methylation (92). Although the exact 
mechanism by which MNU induces gastric carcinomas remains unknown, Runx3 
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appeared to be the major target of the carcinogen, since CpG islands in the Runx1 and 
Runx2 promoter regions were not methylated (92). Ras and p53 genes also do not 
appear to play important role in these changes (96). Collectively, these results 
provided strong evidence that RUNX3 is a tumor suppressor in gastric cancer, 
whereby inactivation of RUNX3 is causally associated with human gastric 
carcinogenesis.  
On a separate investigation, the authors also found that RUNX3 was 
inactivated in more than 80% of gastric cancer not only by gene silencing but also by 
protein mislocalization (97). In a total of 97 gastric cancer samples tested, 44% did 
not express RUNX3. From the remaining 56% that expressed RUNX3, 38% were 
detected exclusively in the cytoplasm, and only 18% showed nuclear localization. 
Unlike RUNX3 in nuclear, those that were expressed in the cytoplasm of cancer cells 
were inactive as tumor suppressor. Several other groups also reported the role of 
RUNX3 in gastric cancer, whereby the lack of RUNX3 function is linked to the 
genesis and progression of gastric cancer (68, 70, 98). Collectively, all these 
observations indicate the importance of RUNX3 in the normal function of stomach as 
well as its role as tumor suppressor in gastric carcinogenesis.  
 
2.5.1 Tumor Suppressive Mechanism of RUNX3  in Gastric Cancer  
 
RUNX3 is a downstream target of the TGF-β signaling pathway, whereby RUNX3 
forms complexes with Smads which in turn regulates target gene expression (99, 100).  
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Runx3 knockout mice which displayed a reduced sensitivity to TGF-β supported the 
notion that RUNX3 operates downstream of the TGF-β signaling pathway (23). 
Apoptosis induced by TGF-β is a well-documented phenomenon that occurs 
in many different cell types (101). The activation of Smad proteins seems to play a 
crucial role in the TGF-β-induced apoptosis, as shown by the induction of apoptosis 
with the overexpression of Smad4 (102), whereas overexpression of a dominant-
negative Smad3 inhibits TGF-β-dependent apoptosis (103). Several proapoptotic 
target genes regulated by the TGF-β signaling pathyway, such as Bcl-2, Bcl-xL, Bax 
and the zinc-finger trasnscription factor (TIEG) were also reported (104-106). 
However, the underlying mechanism mediated by TGF-β that regulates these 
proapoptotic genes was not understood. Recently, Bim was discovered as a 
downstream target of RUNX3. RUNX3 was shown to transcriptionally upregulates 
Bim which functions in the TGF-β induced apoptosis in gastric epithelial cells (107).  
This indicates that RUNX3 plays a role in apoptosis to regulate proliferation of gastric 
epithelial cells.   
TGF-β mediated growth arrest works through two classes of antiproliferative 
gene responses namely the inactivation of cyclin-dependent kinases (cdks) through 
the induction of cdk inhibitors, and the downregulation of c-Myc (108).  It was 
recently reported that RUNX3 mediates the TGF-β induced cell growth arrest in 
gastric epithelial cells by activating the cyclin-dependent kinase inhibitor, p21WAF1/Cip1. 
The authors showed that the overexpression of RUNX3 potentiates TGF-β-dependent 
endogenous p21 induction. RUNX3 also cooperates synergistically with Smad to 
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activate the p21 promoter. This associates the RUNX3 tumor suppressor function to 
its ability to induce cdk inhibitors (109). Taken together, these findings pointed to the 
ability of RUNX3 in inhibiting proliferation, further support the role of RUNX3 as a 
tumor suppressor under the TGF-β pathway in the gastric system.  
 
2.6 Tight junction (TJ) Protein Family  
 
Tight junctions are one of the four main structures regulating cell-to-cell interactions 
in the epithelial and endothelial cells. Adherens junctions (AJ) and desmosomes are 
mainly involved in cell to cell adhesion, and gap junctions in cell to cell 
communication, whereas TJs provide cell to cell contact with a seal between the 
apical portions of adjacent basolateral membranes (110). On ultrathin section electron 
micrographs, TJs are viewed as a series of fusion points between the plasma 
membranes of adjacent cells located at the most apical regions of the junctional 
complex. TJs contain aqueous pores that are permeable to small molecules, such as 
inorganic ions, with size and charge selectivity (111). In normal epithelial tissues, 
various tight junction proteins are connected through protein-protein interactions to 
form a complex that provide tight sealing of the cellular sheets and to control 
paracellular ion flux, thereby maintaining tissue homeostasis. Besides, tight junctions 
help to maintain cell polarity by forming a barrier that prevents diffusion of 
membrane proteins and lipids from the apical to the basolateral cell membrane (112). 
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 Three integral proteins that are found at the TJ include the transmembrane 
proteins, namely occludin, claudins and junctional adhesion molecules (JAMS) (113). 
Occludin and claudins constitute the backbone of TJ strands and are found abundantly 
in the epithelial and endothelial cells, while JAM appears to be important for the 
routine trafficking of T-lymphocytes, neutrophiles and dendritic cells from the 
lymphoid and vascular compartments to the tissues during immune surveillance and 
inflammatory responses (114). There are also TJ proteins found within the myelin 
sheaths, such as the OSP / claudin-11 (115) and PMP22 / gas-3 (116) that play a role 
in the establishment and maintenance of TJs in epithelia of the central nervous system 
(CNS). JAM as its role suggests, belong to the immunoglobulin superfamily of the TJ 
tetraspan proteins (117).  
 Besides, TJ proteins can also be classified into those containing PDZ domains 
such as the MAGUK (membrane associated guanylate kinase homologues) family 
proteins  ZO-1 (118), ZO-2 (119) and ZO-3 (120), the PAR (partitioning-defective 
proteins) (121-123), the MUPP1 (mu
 
lti-PDZ domain protein 1) (124), and the AF-6 / 
Afadin protein, which is found both at the TJs (125) and AJs (126). Other TJ proteins 
that lack PDZ domain include cingulin (127) and symplekin (128). Through protein-
protein interactions, ZOs, AF-6 and cingulin are recruited to form a complex with the 
TJ on the plasma membrane, providing a link to the actin cytoskeleton for transducing 




2.7 Claudin Superfamily 
  
2.7.1 Emergence of Claudin Superfamily 
 
In 1991, a novel and unique sequence named RVP.1 was found during the studies of 
genes that were up-regulated in rat ventral prostate epithelial cells in response to 
androgen withdrawal (129). Six years later, a receptor for the Clostridium perfringens 
enterotoxin (CPE-R) was characterized (130). With this, the high homology between 
the RVP.1 and CPE-R was revealed. RVP.1 and CPE-R were since renamed as 
claudin-3 and claudin-4 respectively and were functionally deomonstrated to be the 
low affinity and high affinity receptor for CPE respectively (131). In 1996, an 
oligodendrocyte-specific protein, which was renamed claudin-11, with homology to 
claudin-3 and claudin-4 was discovered (132, 133). In 1998, with the findings of two 
homologous novel molecules, named claudin-1 and claudin-2, which was discovered 
to form normal appearing, functional tight junctions in the absence of occludins, the 
claudins were recognized as a new superfamily of homologous protein that 
contributes to the major structural and functional components of tight junctions (134). 
Claudins were named after the Latin word ‘claudere’ – to close. To date, at least 23 
members of the claudin family have been identified in mouse and human, mainly 





2.7.2 Evolution of Claudin Genes Family   
 
Claudins are crucial members of the transmembrane tetraspan family that constitute 
the tight junctions, usually present on the membranes of epithelial and endothelial 
cells and thus are found throughout the body (135). Individual claudin family 
members can be expressed ubiquitously or is cell-type specific (136). Besides, 
individual cells can express either multiple claudin family members or a single 
claudin species (135, 136).  
 Invertebrates such as C. elegans or D. melanogaster only possess four to five 
claudin-related genes (137, 138). This is in contrast to the many claudin genes present 
in mammals. This, together with the frequently observed tissue- and cell-type specific 
expression of individual claudins in mammals (136, 139), indicates that the expansion 
of the claudin gene family in parallel with the evolution of increasingly complex 
tissue and organs was probably to accommodate new or overlapping functions. A 
total of 56 Fugu claudin genes have also been identified in the teleost fish, Fugu 
rubripes (Fugu), with 35 of them having orthology to 17 mammalian claudin genes, 
and the remaining 21 genes being specific to the fish lineage. The more or less tissue-
specific or developmental stages-specific expression of Fugu claudin genes supported 
the notion that the expansion of claudin gene family during evolution was probably to 
allow acquisition of novel functions and to contribute to the distinct physiology of 




2.7.3 Claudin Protein Structure and Functions 
  
A typical claudin superfamily protein has a molecular weight of ~21 kDa. The 
putative protein structure of claudins is predicted to consist the cytoplasmic N- and C-
termini, four transmembrane domains, and two extracellular loops (Figure 2.4c). 
Among the claudins, the amino acid sequences of the first and fourth transmembrane 
segments and the first and second extracellular loops are highly conserved, whereas 
the sequence of the second and third transmembrane segments are more diversified. 
The first extracellular loop is larger and more hydrophobic than the second 
extracellular loop and is believed to bridge the intercellular space. Claudins on 
adjacent cells interact with each other through these extracellular loops (141).  
The tight junction protein occludin has the same tetraspanning structure like 
claudins. However, claudins are the main tight junction proteins that function in the 
sealing of the TJ (142). The crucial task of claudins in the TJs was highlighted by the 
following evidence. Firstly, claudin-1 co-localizes with occludin in the most apical 
regions of the second layer of the stratum granulosum in the skin. Epidermal barrier 
of claudin-1 deficient mice was severely affected leading to dehydration, wrinkled 
skin and death of mice within 1 day of birth. In the wild-type epidermis which was 
positive for both claudin-1 and occludin, TJs efficiently prevented the diffusion of 
subcutaneously injected tracer. The claudin-1 deficient and occludin positive 
epidermis however failed to prevent this diffusion from happening, indicating that 
claudin-based TJs in combination with occludin are crucial for the barrier function 
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(143). Secondly, transfection of claudin into human breast cancer cells that have lost 
the expression of claudin-1 decreases the paracellular flux of tracer despite the 
absence of occludin (144).  
Claudins function by limiting the exchange of lipids between the apical and 
basal membranes of epithelial and endothelial cells, hence define the membrane 
polarity, provide a continuous intercellular seal, and regulate the paracellular 
transport of water, solutes and immune cells (112, 145-147) (Figure 2.4a and b). The 
tight sealing function of claudins is also probably mediated through phosphorylation 
at the cytoplasmic C-terminus of claudins which has the consensus motifs of protein 
kinase C (PKC), casein kinase II and cyclin adenosine monophosphate (cAMP)-
dependent kinase. Different claudin species possess different type and number of 
phosphorylation site, suggesting the role of C-terminus in different functions between 
claudin species. Phosphorylation at this region by proteins such as mitogen-activated 
protein kinase (MAPK) and cAMP-dependent kinase, resulted in increased 
permeability of tight junctions, probably through the removal of claudin from the 
tight junction (148, 149).  
Claudins being the major component of tight junctions, interact directly with 
occludin and zonula occludens (ZO), and indirectly with AF-6 and the myosin-
binding molecule cingulin (150-152). Claudins bind to the PDZ-domain-containing 
proteins such as ZO-1, -2 and -3 through its PDZ-binding motif at the C-terminal 
region. As ZO proteins function as scaffolding proteins which are able to bind to 
cytoskeletal proteins, interactions between claudins and ZO proteins promote 
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scaffolding of the tight junction transmembrane proteins, providing a link to the actin 
cytoskeleton for transducing regulatory signals to and from tight junctions (153). Due 
to its crucial role in regulating signaling pathways, loss of normal tight junction 
functions, especially those that are related to claudins has been widely linked to a 














Figure 2.4: Claudin-based tight junctions in simple epithelia. (a) Location of TJs at 
the most apical region of lateral membranes. (b) Enlargement of the boxed area in (a). 
TJ strands are embedded within the lipid bilayer of each membrane. Each TJ strand 
tightly associates with another TJ strand in the opposing membrane of adjacent cells 
to form a paired strand. (c) Enlargement of the boxed area in (b). Structure of 
claudins. It bears four transmembrane domains with a short cytoplasmic tail and two 




2.8 Claudin and Cancer 
 
Depending upon the cancer type, expression of claudins were observed to be 
diminished or elevated in cancer cells compared to normal adjacent cells or tissue 
(Table 2.2). Although the aberrant expression of claudins in cancer has been well 
established, whether claudins play a functional role in tumorigenesis and cancer 
progression remains unclear.  
Based on its primary role in the formation of tight junctions, it has been 
hypothesized that the loss of claudin expression may reduce cell adhesion, hence 
increase tumor cell motility and invasive potential. In line with this hypothesis, a 
correlation has been established between the loss of tight junction protein claudin-7 
and the invasiveness of ductal carcinoma of the breast (158). Besides, the loss of 
claudin expression was also associated with increased motility and invasiveness 
during epithelial mesenchymal transition (160, 161). In vitro studies by 
overexpression claudin-4 in gastric and pancreatic cancer cell lines also showed 
decreased motility, invasiveness and anchorage-independent growth (162, 163). In 
addition, mice injected with pancreatic cancer cells overexpressing claudin-4 formed 







Table 2.2: Claudin expression in human cancer 
Cancer type Claudin involved Expression 
pattern 
References 
Colon 1 Elevated (164) 






Prostate 3, 4 Elevated (159) 




(158, 169, 170) 
(171) 
Hepatocellular  carcinoma 10 Elevated (172) 
Ovarian 3, 4 Elevated (173) 
Head and neck 7 Diminished (174) 
Melanoma 1 Diminished (175) 
Pancreatic 4 Elevated (176) 
 
 
Paradoxically, small interfering RNA (siRNA) knock-down of claudin-3 and 
claudin-4 in ovarian cancer cell lines inhibited invasive ability, consistent with the 
increase of motility and invasiveness when these two genes were overexpressed in 
human ovarian surface epithelial cells (177). Overexpression of claudin-1 in colon 
cancer cells resulted in increased tumor growth and metastasis in vivo, whereas 
siRNA knock-down of claudin-1 in metastatic colon cancer cells inhibited migration 
and invasion (178). This apparently contradicting role of claudins in different cancers 
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suggests that claudins may have cell-specific effects and that a balance of claudin 
expression is physiologically necessary. A shift in either direction may result in the 
disruption of the function and alterations in cellular behavior. This phenomenon could 
well be demonstrated whereby both claudin-1 knock-down and claudin-6 
overexpression were lethal due to defect in epithelial barrier function (143, 179). 
 
2.8.1 Claudin and Gastric Cancer 
 
Among the claudin family members, claudin-1, -3, -4, -7, -18 and -23 have been 
reported to play a role in gastric cancer. It was reported that diffuse type of gastric 
carcinomas shows lack of claudin-1 and claudin-4 expression (169). A tissue 
microarray study also shows a lower expression of claudin-1, -3 and -4 in diffuse type 
of gastric cancer (165). Study by Lee et al. observed that loss of claudin-4 promotes 
the advancement of gastric adenocarcinoma (155). Quantitative RT-PCR and 
immunostaining method also revealed the down-regulation of claudin-18 in intestinal 
type of gastric cancer, which was postulated to be an early event in gastric 
carcinogenesis (166). Claudin-23 on the other hand, was found to be down-regulated 
in the intestinal type of gastric cancer (167). All these reports pointed to the link of 
the diminished level of claudins and gastric carcinogenesis. On the contrary, reports 
also show the up-regulation of claudin-4 and -7 in gastric cancer (139, 162). Despite 
all these findings, the mechanism by which various claudins are regulated and their 
function in gastric cancer is still poorly understood.   
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2.9 Crosstalk of TJ Components with Signaling Pathways 
 
β-catenin was reported to regulate claudin-1 expression, evidenced by the 
decreased in claudin-1 expression when intracellular β-catenin was reduced by 
adenovirus-mediated transfer of wild-type APC into the APC-deficient colon cancer 
cells. Two putative Tcf4 binding elements in the claudin-1 promoter were tested to be 
responsible for activating its transcription. Primary colorectal cancers also expressed 
higher level of claudin-1 as compared to the adjacent noncancerous mucosa, 
indicating that claudin-1 is involved in the β-catenin-Tcf / LEF signaling pathway, 
and increased expression of claudin-1 may have some role in colorectal 
carcinogenesis (164). Likewise, activity of the claudin-2 promoter was elevated in 
mouse mammary epithelial C57 cells expressing Wnt-1. Expression of LEF-1 and 
beta-catenin also enhanced claudin-2 promoter activity, which was reduced when the 
LEF-1 binding sites within the claudin-2 promoter was mutated (180).  
The beta-catenin signaling pathway is activated in the MDCK cells expressing 
(181) the mutant ZO-1 protein which encodes the PDZ protein, but no longer 
localizes at the plasma membrane. These cells also induce a dramatic epithelial to 
mesenchymal transition (EMT), indicating the loss of ZO-1 function in tumor 
metastasis initiation (182). Exogenous transfection of ZO-1 on the other hand was 
reported to activate the Membrane-type 1 Matrix Metalloproteinase (MT1-MMP) 
expression and cell invasiveness by concomitantly activating the beta-catenin / TCF / 
LEF signaling pathway in the human breast cancer cells (181).  
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Mitogen-activated protein (MAP) kinases are Ser / Thr protein kinases that 
respond to extracellular stimuli such as growth factors and stress. There are four 
distinct groups of MAPKs present in mammals. The first known as the classical MAP 
kinases or the extrcellular signal-regulated kinases (ERKs) is activated by growth 
factors and regulates cell proliferation and differentiation. c-Jun N-terminal kinases 
(JNKs) and p38 isoforms are two other groups of MAPKs activated by stress stimuli 
and involved in cell differentiation and apoptosis. The forth group, named ERK5 is 
activated by growth factors and stress stimuli and is involved in cell proliferation.    
MAPK signaling pathway modulates TJ paracellular transport by up- or 
down-regulating the expression of several TJ proteins. Activation of the MAPK 
pathway can lead to TJ opening which perturbs the barrier function, or the assembly 
of TJ which promotes barrier function. Treatment with the cytokine IL-17 activated 
the ERK1/2 and increased the expression of claudin-1 and -2 in intestinal cells, which 
also increased the barrier function of TJs (183). Similarly, the expression of claudin-1 
and ZO-2 which were upregulated by TGF-β in kidney and intestinal cells 
respectively through the activation of ERK1/2 also increased TJ barrier function (184, 
185). On the other hand, Ras transfected MDCK cells show perturbs TJ barrier 
function due to the absence of occludin, claudin-1 and ZO-1 (186). In mouse hepatic 
cell lines, transfection with oncogenic Raf also decreased claudin-2 expression, 
altering the distribution of ZO-1 at cell borders and perturbs TJ barrier function (187).  
The Snail family of transcription factors which function under the MAPK 
pathway were also identified to regulate claudin-1 expression. In human epithelial 
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cells and invasive human breast tumors, high levels of Snail and Slug were correlated 
with low levels of claudin-1 expression, indicating the Snail family transcription 
factors as repressors of claudin-1 (188). Other tight junction proteins including 
claudin-3, -4 and -7, occludin and ZO-1 were also reported to be down-regulated by 
Snail (160, 189).  
Several growth factors and cytokines were also identified to affect claudin 
expression under the MAPK pathway. The tumor promoting factors hepatocyte 
growth factor (HGF) and epidermal growth factor (EGF) were shown to decrease 
claudin-7 expression and increase claudin-1, -3 and -4 expressions (158, 190). 
Exposure of the cytokines tumor necrosis factor α (TNF-α), interleukin 1β (IL-β) and 
IL-17 also cause increased claudin-1 expression (183).  
 
2.10 TJ, AJ and Mechanism in Tumor Metastasis 
 
Tight junctions are crucial players in the normal function of epithelial cells, such as 
the regulation of proliferation and differentiation. According to the theory proposed 
by Mullin (2004), when tight junction barrier functions are interrupted due to the loss 
of claudins expression, growth factors and cytokines freely penetrate from the 
surrounding tissue, increasing paracellular flux of growth factors, which subsequently 
give rise to auto- and paracrine stimulation of tumorigenic epithelial cells (Figure 2.5). 
This lowering of diffusion barrier leads to an improved nutrient supply and adds to 











Figure 2.5: Model of claudin-based TJ and its alteration during cancer progression 
due to the loss of claudin expression and reconstitution in an experimental cancer 
model. In normal epithelial tissues, the passage of solutes including growth factors 
and cytokines, is regulated through the normal paracellular fence function of TJs, 
consisting of an intact basement membrane and endogenous claudin expression. Only 
a limited amount of these factors traverse the cell membrane to reach the tissue 
stromal. In in situ or invasive cancer, loss of claudin expression and breakdown of TJ 
barrier functions allow growth factors and cytokines to penetrate freely from the 
surrounding tissue. With the reconstitution of claudin expression, some or all the TJ 
functions are restored, resulting in a reduced paracellular flux of growth factors 
[Ref.191]. 
 
It is well-known that tumor metastasis can be initiated by epithelial-
mesenchymal transition (EMT) (193). This cellular transformation results in the loss 
of cell adhesion and apical-basal polarity, followed by a shift in cytoskeletal 
dynamics from epithelial toward the mesenchymal phenotype. This alteration in 
cellular morphology is typically characterized by changes in cell polarity and loss of 
adhesion protein such as E-cadherin. Suppression of E-cadherin has been linked to 
various transcription factors such as Snail, Slug, SIP-1, ZEB-1, E12 / E47 (194, 195) 
and Twist (196). 
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It was known that up-regulation of Snail expression by MAPK and PI3K are 
responsible for suppressing approximately half of the total cellular E-cadherin (194). 
However, full repression of E-cadherin was shown to associate with nuclear 
localization and transcriptional activities of Smad4 and LEF-1, suggesting that both 
Snail and LEF-1 are necessary for complete loss of E-cadherin and completion of 
TGF-β1-induced EMT (Figure 2.6). Up-regulation of Snail also inhibits expression of 
claudin-1, claudin-2 and occludin. Both Smad-dependent and Smad-independent 
signaling pathways were shown to be necessary for EMT (161).  
Downregulation of ZO-1 through the beta-catenin / TCF / LEF (182) and 
MAPK pathway (197) as well as suppression of occludin through the Snail 
transcription family (160, 198, 199) were also linked to the formation of EMT. Snail 
up-regulation through the MMP-3-Rac1-ROS pathway was also reported to promote 
EMT (200). Other pathways such as Notch (201, 202) and RhoA (203, 204), (205) 







































Figure 2.6: A schematic representation of the proposed TGF-β1 signaling mechanism 
that promotes EMT. Up-regulation of Snail expression happens in response to early 
signaling through Ras-Raf-MEK-ERK-AP-1. Snail then inhibits expression of 
claudin-1, claudin-2 and occludin. Snail causes partial loss of E-cadherin, decreasing 
the level of substrate for β-catenin. Further stabilization of cytoplasmic β-catenin is 
achieved through PI3K signaling, through phosphorylation and deactivation of p-
GSK-3 β by AKT downstream of PI3K. Absence of p-GSK-3β inhibits the ubiquitin 
proteosome pathway and degradation of β-catenin and Snail. Smad signaling, 
controlled through endocytosis of TGF-β receptor complex, promotes transcription of 
LEF-1, an alternative substrate for β-catenin, through the Smad2/3-Smad4 
transcription complexe. In early endosome, TβR1 phosphorylates Smad proteins upon 
their recruitment by SARA. SARA binds to PIP3 for proper association with the 
receptor. Formation of β-catenin / LEF-1 complexes acts to transcribe genes that 




The vascular endothelial (VE)-cadherin at AJ has recently been reported to 
up-regulate the gene encoding TJ protein claudin-5 by inducing the phosphorylation 
of FoxO1 through Akt activation and by limiting the translocation of beta-catenin to 
the nucleus (206). These results offer a molecular basis for the link between AJ and 
TJ in maintaining cell function. Although AJ and TJ can be functionally linked, 
reports have also shown that AJ assembly is not a pre-requisite for TJ formation (186, 
207, 208). Inactivation of the von Hippel-Lindau (VHL) gene in the kidney epithelium 
triggers a downregulation of TJ molecules occludin and claudin-1, resulting in a 
dismantling of intercellular junctions and EMT. However, the disruption of these TJ 
proteins is not dependent on E-cadherin downregulation as re-expression of E-
cadherin in von Hippel-Lindau (VHL) defective cells did not rescue TJ formation nor 
restore an epithelial-like cell shape (209).  
Another mechanism of EMT was recently reported by Lehembre et al. (2008) 
(210) (Fig. 2.7). The authors demonstrated that the loss of E-cadherin function up-
regulates expression of the neuronal cell adhesion molecule (NCAM). A subset of 
NCAM translocates from the fibroblast growth factor receptor (FGFR) complexes 
outside lipid rafts into lipid rafts where it stimulates the non-receptor tyrosine kinase 
p59 (Fyn), leading to the phosphorylation and activation of the focal adhesion kinase 
(FAK) and the assembly of β1-integrin-dependent focal adhesion assembly in cells 
that retain epithelial-mesenchymal plasticity. NCAM is not only needed for induction 
of EMT but also for maintenance of the mesenchymal state. Enforced expression of 
NCAM promotes mesenchymal-like properties in some epithelial cells in culture. 
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High NCAM expression is also correlates with tumor invasion. On the contrary, 
abolition of NCAM expression during EMT inhibits focal adhesion assembly, cell 
spreading and EMT. This proposed model established a link between the loss of E-




Figure 2.7: Putative NCAM-associated signaling changes during EMT. Induction of 
EMT, induced via TGF-β or cadherin loss, causes NCAM-mediated weakening of 
cell-cell adhesions and also formation and dynamic turnover of focal adhesions.  
Elevation in NCAM expression leads to altered signaling complexes. NCAM binding 
to PLCγ and cortactin is diminished, and forms a complex with Fyn and FAK. These 
signaling induce a more mesenchymal and migratory phenotype associated with 
aggressive cancers of epithelial origin. Knockdown of NCAM induces the reversal of 













hCldn1-F: 5’-CCAACGCGGGGCTGCAGCT-3’  





hRUNX3 (Identifier, Hs00231709_m1) 
Primers for quantitative real time RT-PCR (pre-made by ABI) 
hclaudin-1 (Identifier, Hs00221623_m1) 
hGAPDH (Identifier, Hs99999905_m1) 
 
hclaudin-1 promoter 1530-F:  
Primers for cloning hclaudin-1 promoter 
5’-CGGGGTACCCCCTGGGATACAACACG-3’ (KpnI site at 5’) 
hclaudin-1 promoter 1530-R:  




Primers for cloning mclaudin-1 ORF with Myc-Tag into pcDNA3.1/HisC 
5’-CGAGATATCATGGCCAACGCGGGG-3’ (EcoRV site at 5’) 
mclaudin-1 ORF/Myc-R: 
5’-GTATGCGGCCGCGTCGACTCACAG-3’ (NotI site at 5’) 
 
AShclaudin-1 ORF-F: 
Primers for cloning AS hclaudin-1 ORF into pcDNA3.1/HisC 
5’-CTATTGCGGCCGCATGGCCAACG-3’ (NotI site at 5’) 
AShclaudin-1 ORF-R: 
5’-GGCGGCCGATATCTCACACGTAGTC-3’ (EcoRV site at 5’) 
 
Cldn1PromMut1F:  
Primers for SDM on 1st RUNX binding site on hclaudin-1 promoter 
5’-GCTTCCCCTCCCATT

























Primers for SDM on 1st + 2nd  RUNX binding site on hclaudin-1 promoter 
5’-GCT TCCCCTCCCA TTACACTCGCATT
Cldn1PromMut1+2R: 





Primers for mutagenesis check 







Cldn1CHIP-2F: 5’ AAAACCATAGAAGCTTCCCCTCCC 3’  
ChIP primers for amplifying hclaudin-1 (specific for hclaudin-1 promoter) 
Cldn1CHIP-2R: 5’ CCTCTATGTTTCTCCAAAGCTTCC 3’ 
 
FOR: 5’-TACTAGCGGTTTTACGGGCG-3’  
ChIP primers for amplifying GAPDH (specific for GAPDH promoter) 
REV: 5’-TCGAACAGGAGGAGCAGAGAGCGA-3’ 
 
3.1.2 Oligonucleotide probes for EMSA 
 
WT-WT:  























3.1.3 Commercial kit 
 
RNeasy mini kit, 74104, Qiagen  
Omniscript reverse transcription kit, 205111, Qiagen 
TaqMan Fast Universal PCR Master Mix, 4352042, Applied Biosystems 
QuickChange XL site-directed mutagenesis kit, 200516, Stratagene 
Dual-Luciferase Reporter Assay System, E1910, Promega 
EnVision+ system (DAB), K4010; Dako 
NE-PER Nuclear and Cytoplasmic Extraction Reagents, 78833, Pierce 
Biotechnology 
LightShift Chemiluminescent EMSA kit, 20148, Pierce Biotechnology 
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EZ ChIP Chromatin Immunoprecipitation kit, 17-371, Upstate cell signaling 
solutions 





Anti-RUNX3 (R3-5G4), mAb, mouse IgG, 0.5 µg/ml; a monoclonal antibody against 
RUNX3 established in our laboratory 
Anti-RUNX3 (R3-6E9), mAb, mouse IgG, 0.7 mg/ml; a monoclonal antibody 
against RUNX3 established in our laboratory 
Anti-Claudin-1, pAb, rabbit IgG, 0.5 ml concentrate, 18-7362, Zymed 
Anti-Claudin-2, pAb, rabbit IgG, 0.25 µg/µl, 51-6100; Zymed 
Anti-Claudin-3, pAb, rabbit IgG, 0.25 µg/µl, 34-1700; Zymed 
Anti-Claudin-4, pAb, rabbit IgG, 0.25 µg/µl, 36-4800; Zymed 
Anti-Claudin-7, pAb, rabbit IgG, 0.25 µg/µl, 34-9100; Zymed 
Anti-Claudin-11, pAb, rabbit IgG, 0.25 µg/µl, 36-4500; Zymed 
Anti-Claudin-16, pAb, rabbit IgG, 0.25 µg/µl, 34-5400; Zymed 
Anti-ZO-1, pAb, rabbit IgG, 0.25 µg/µl, 61-7300; Zymed 
Anti-ZO-2, pAb, rabbit IgG, 0.25 µg/µl, 71-1400; Zymed 
Anti-ZO-3, pAb, rabbit IgG, 0.25 µg/µl, 36-4100; Zymed 
Anti-Occludin, pAb, rabbit IgG, 0.25 µg/µl, 71-1500; Zymed 
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Anti-E-cadherin, mAb, mouse IgG, 250 µg/ml, 610181; BD Pharmingen 
Anti-β-actin, mAb, mouse IgG, AC-15; Sigma 
Donkey Anti-Rabbit IgG, Horseradish Peroxidase linked whole antibody, 1 ml, 
NA934V; Amersham Pharmacia Biotech 
Sheep Anti-Mouse IgG, Horseradish Peroxidase linked whole antibody, 1 ml, 
NA931V; Amersham Pharmacia Biotech 
Normal Mouse IgG, 200 µg, sc-2025, Santa Cruz Biotechnology 
Biotinylated Goat Anti-Rabbit IgG (H + L), 1.5 mg, BA-1000, Vector Labs 
 
Fluorescein Avidin D, 5 mg, A-2001, Vector Labs 
 
3.1.5 General Buffer Preparation 
 
Phosphate buffered saline (PBS) [137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 
1.4 mM KH2PO4, pH7.4] 
TE buffer [10 mM Tris-HCL, 1mM EDTA, pH 8.0] 
 
LB broth [1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 0.5% (w/v) 
NaCl; pH 7.0] 
Bacteria Transformation 
LB agar [1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 0.5% (w/v) NaCl, 
2% (w/v) Bacto-agar] 
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SOC media [2% Bacto-tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCL, 10 
mM MgCl2, 10 mM MgSO4, 20 mM glucose] 
NZY broth [1.0% NZ amine (Casein hydrolysate), 0.5% NaCl, 0.5% Yeast Extract, 
0.2% MgSO4, 0.2% MgCl2, 20 mM glucose] 
 
10X TBE [0.89 M Tris, 0.89 M Boric Acid, 0.02 M EDTA] 
Agarose Gel Electrophoresis 
6X Sample loading buffer [0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene 
cyanol, 30% (v/v) Glycerol] 
 
Tris, pH 8.8 [1.5 M Tris base, 0.4% (w/v) SDS, pH adjusted to 8.8 with concentrated 
HCl] 
SDS-PAGE and Western Blotting 
Tris, pH 6.8 [0.5 M Tris base, 0.4% (w/v) SDS, pH adjusted to 6.8 with concentrated 
HCl] 
10X Laemli running buffer [0.25 M Tris base, 1.92 M Glycine, 1% (w/v) SDS] 
Towbin transfer buffer [10% (v/v) 10X Laemli buffer, 20% (v/v) Methanol] 
Blocking buffer [5% skim milk powder in 1X PBS]  
Wash buffer [1X PBS, 0.1% Tween 20]  





10% Resolving Gel:     
SDS-PAGE Gel 
30% Acrylamide 3.3 ml 
1.5 M Tris (pH 8.8) 2.5 ml  
10% APS  0.1 ml 
10% SDS  0.1 ml 
TEMED         0.004 ml 
dH2O           4.0 ml 
Total volume           10.0 ml 
 
6% Resolving Gel:     
30% Acrylamide 2.0 ml  
1.5 M Tris (pH 8.8) 2.5 ml  
10% APS  0.1 ml   
10% SDS  0.1 ml   
TEMED                  0.008 ml            
dH2O   5.3 ml    
Total volume           10.0 ml 
 
5% Stacking Gel: 
30% Acrylamide 0.17 ml 
1.0 M Tris (pH 6.8) 0.13 ml  
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10% APS  0.01 ml 
10% SDS  0.01 ml 
TEMED           0.001 ml 
dH2O   0.68 ml   
Total volume               1.0 ml 
 
4% PFA [Add 16 g of PFA to approximately 300 ml of preheated dH2O; Use NaOH 
to dissolve mixture and add 40 ml of 10X PBS; measure pH and adjust with 1 M HCl 
till pH reaches 7.2-7.4; top up to 400 ml with dH2O and filter]  
Tissue Fixation 
 
Lysis buffer [9 M Urea; 2% Triton-X; 5% final concentration of 2-mercaptoethanol 




30% polyacrylamide  2.2 mL 
0.5X TBE Gel (1.5 mm SDS-PAGE plate) 
1X TBE   6.6 mL 
10% APS   110 µL 
TEMED     11 µL 
dH2O    4.4 mL 





3.2.1 Establishment of Gastric Epithelial Cell Lines 
 
Runx3 knock out mice was collaboratively generated by Drs. Kosei Ito (Kyoto 
University, Japan) and Suk-Chul Bae (Chungbuk National University, South Korea) 
as described in Li et al. (2002). In brief, A phage DNA clone containing exon 3 of the 
Runx3 gene was isolated from a 129/SvJ mouse genomic library (Stratagene). The 
LacZ gene was introduced into the Sma1 site (12th codon in-frame) of exon 3 of the 
phage clone to generate a gene-targeting vector (appendix 1). The generated plasmid 
was transfected by electroporation into the E14 mouse ES cells. Correctly targeted ES 
cells were injected into C57BL/6 blastocysts, and the resulting chimeras were crossed 
with C57BL/6 females. p53-deficient mice with C57BL/6 genetic background was  
provided by Drs. Aizawa S and Katsuki M and generated as described previously by 
Tsukada T et al. (1994) (211).  
All mouse gastric epithelial cell lines used in this experiment were generated 
and provided by Dr. Hiroshi Fukamachi (University of Tokyo, Japan) through 
crossing the Runx3 and p53 knock out mice. All animal experiments were carried out 
in accordance with the guidelines for the care and use of laboratory animals of 
University of Tokyo. Runx3+/-p53+/- mice were mated to obtain Runx3-/-p53-/- and 
Runx3+/+p53-/- fetuses (Figure 3.1). Gastric epithelial cells from 16.5-day fetuses were 
separated from attaching mesenchymes by treating gastric tissues with 30 mM 
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EDTA-Hanks’ solution and cultured separately in wells precoated with rat tail 
collagen gels. Cells were seeded in Ham’s F12 medium (Sigma) supplemented with 
10% horse serum (Trace Biosciences), bovine pituitary extract (100 µg/ml; Gibco-
BRL), epidermal growth factor (10 ng/ml; Upstate Biotechnology), insulin (3 µg/ml; 
Sigma), cholera toxin (300 ng/ml; List Biological Laboratories), and hydrocortisone 
















Figure 3.1: Schematic diagram showing the generation of Runx3+/+p53-/- and 




pups at E16.5 dpc 
                Runx3+/+ p53-/-          Runx3-/- p53-/- 
100% pure epithelial cells 
(culture on collage) 
Runx3+/+ p53-/-                Runx3-/- p53-/- 
   cell lines                             cell lines 
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Rapidly growing cells were treated with trypsin-EDTA and dispersed cells 
were re-seeded on new collagen gels in the first 5-7 passages, and on plastic 
substratum after 6-8 passages. Once the cells began to proliferate rapidly on plastic 
substratum, at about passage number 12, the culture medium was changed to 
Dulbecco’s modified Eagle’s medium (Sigma) supplemented with 10% fetal bovine 
serum (Sigma), as cells grow faster in this medium. GIF5 and 14 cells were 
established from Runx3-/-p53-/- mice while GIF9 and 13 cells were established from 
Runx3+/+p53-/- mice.  
 
3.2.2 Cell Lines and Cell Culture 
 
SNU16 gastric cancer cell line was maintained in RPMI-1641 medium supplemented 
with 10% fetal bovine serum (BDH Biosciences). AGS and 293T cells were cultured 
in DMEM supplemented with 10% fetal bovine serum. GIF cells (Runx3+/+ and 
Runx3-/-) were maintained in Ham’s F-12 medium (Sigma) supplemented with 10% 
horse serum (Trace Biosciences), bovine pituitary extract (100 µg/ml; Gibco-BRL), 
epidermal growth factor (10 ng/ml; Upstate Biotechnology), insulin (3 µg/ml; Sigma), 
cholera toxin (300 ng/ml; List Biological Laboratories), and hydrocortisone (3 µg/ml; 
Sigma), and cultured in a humidified atmosphere of 5% CO2 in air at 37°C. When the 
cells reach passage number 12, the culture medium was changed to Dulbecco’s 




3.2.2.1 Treatment of Cells by TGF-β1 
 
Regulation of target genes by TGF-β was observed by treating cells with the 
recombinant human TGF-β1 (R&D systems, USA). SNU16 and ASSNU16 cells were 
treated with 3 ng/ml of TGF-β1. Cells at 0 hr before treatment and 6, 12 and 24 hr 
after treatment were collected for protein extraction, followed by Western blot 
analysis.  
To observe the effect of TGF-β inhibitor on the expression of claudin-1, same 
number of SNU16 cells was seeded and grown overnight in three separate 75 cm3 
flask. One flask of cells was added 3 ng/ml of TGF-β1, another flask with same 
amount of TGF-β1 and 1 µg/ml of TGF-β inhibitor (SB431542) (GlaxoSmithKline 
Pharmaceuticals). The flask without any treatment was used as control. After 24 hr 
treatment, cells were collected and protein extraction from these cells was performed. 
Protein samples were used for Western blot analysis.  
 
 
3.2.3 Semiquantitative RT-PCR, Quantitative RT-PCR   
 
Total RNA was extracted from SNU16 cells and AS SNU16 cells using the RNeasy 
mini kit (Qiagen) and cDNAs were synthesized from total RNA using the Omniscript 
reverse transcription kit (Qiagen) according to the manufacturer’s protocol. 
Semiquantitative reverse transcription-PCR (RT-PCR) for the detection of hClaudin-
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1 was carried out using the hCldn1-F and hCldn1-R primers, whereas detection of 
GAPDH was carried out using the Hu_Gapdh-F and Hu_Gapdh-R primers.  
Quantitative RT-PCR was performed on cDNA from SNU16 control cells 
stably expressing pcDNA3 and SNU16 stable cells expressing Flag-Runx3 using the 
real-time TaqMan Fast Universal PCR Master Mix system on an ABI PRISM 
7900HT instrument (Applied Biosystems) for the detection of hRUNX3 (identifier, 
Hs00231709_m1) and hclaudin-1 (identifier, Hs00221623_m1). hGAPDH (identifier, 
Hs99999905_m1) was used for normalization. Analysis was performed using the 
SDS database (version 2.2.1).  
 
3.2.4 Protein Isolation  
 
Adherent cells with 90% confluency were washed twice with ice-cold PBS. 10% of 
ice-cold TCA (in PBS) was added to the cells and incubation at 4 ºC for 20 minutes 
was carried out. Cells were rinsed with ice-cold PBS twice and harvested into a 1.5 
ml eppendorf tube using a rubber policeman. Cells were centrifuged to collect cell 
pellet. Protein lysis buffer were added to the cell pellet followed by sonication twice 
for approximately 10 sec each on ice until cells were completely lysed. 1 µl of protein 
lysate was used for protein concentration measurement using the Bradford method on 
the Beckman Coulter DU530 machine. The remaining protein lysate were added 10% 
lithium dodecyl sulphate (LDS) to a final concentration of 2%. Samples were kept on 
ice and were ready to load. Suspension cells were collected from culture flask into 
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falcon tube and centrifuged to collect cell pellet, which was then rinsed twice with 
ice-cold PBS. Washed pellet was added protein lysis buffer and the same extraction 
procedure was carried out as above. 
 
3.2.5 SDS-PAGE and Western Blot Analysis 
 
SDS-PAGE was run in 1X Laemli buffer at 100 V for approximately 1.5 hr until the 
bromophenol blue dye migrated out of the gel. Proteins on SDS-PAGE gel were 
transferred to the PVDF membrane (pretreated with methanol) using the Western 
blotting apparatus (BioRad). Western blot was carried out in transfer buffer at 70 V 
for 90 min at 4 ºC. Transferred membrane was blocked with 5% skim milk in PBS for 
1 hr, rinsed once with PBST and incubated with the respective primary antibody at 4 
ºC overnight. Membrane was washed three times for 5 min each with 1X PBST, 
followed by incubation with HRP-conjugated secondary antibody for 1 hr at RT. 
Membrane was washed again three time for 5 min each with 1X PBST, and develop 
with the chemiluminescence detection solutions (Amersham Pharmacia Biotech.) 
using an X-ray film developer (Kodak).   
Western blot for the detection of claudin-1, claudin-2, claudin-3, claudin-4, 
claudin-7, claudin-11, claudin-16, ZO-1, ZO-2, ZO-3, occludin, E-cadherin and β-
actin expression in GIF cells and SNU16 cells was performed using a final 
concentration of 1:200 dilution for anti-claudin-1, 1 µg/ml for anti-claudin-2, 1 µg/ml 
for anti-claudin-3, 1 µg/ml for anti-claudin-4, 1 µg/ml for anti-claudin-7, 2 µg/ml for 
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anti-claudin-11, 2 µg/ml for anti-claudin-16, 0.5 µg/ml for anti-ZO-1, 1 µg/ml for 
anti-ZO-2, 2 µg/ml for anti-ZO-3, 0.25 µg/ml for anti-occludin, 1:2500 dilution for 
anti-E-cadherin (BD Pharmingen) and 1:10000 dilution for β-actin (Sigma) 
antibodies, respectively. Expression of RUNX3 in SNU16 and AS SNU16 cells were 
detected using 0.05 ug/ml of anti-RUNX3 (R3-5G4) (97).  
 
3.2.6 Promoter Assay 
 
3.2.6.1 Cloning of  hclaudin-1 Promoter 
 
The promoter region of human claudin-1, which span a segment of 1.53 kb upstream 
from the claudin-1 transcription start site (appendix 2), was amplified from the 
SNU16 genomic DNA by PCR using the hclaudin-1 promoter 1530-F and hclaudin-1 
promoter 1530-R primers. PCR was carried out at 94ºC for 1 min, and 35 cycles of 
94ºC for 30 sec, 68ºC for 30 sec, 72ºC for 2 min and a final cycle at 72ºC for 5 min 
using the Pfu Ultra polymerase (Stratagene). The amplified DNA segment was cloned 
into the pGL3-Basic vector (Promega) (appendix 3) between the KpnI and SacI sites. 
Ligation product was transformed into the E. coli DH5α strain. Positive clones were 
picked and checked by sequencing. One clone with the right sequence was selected 





3.2.6.2 Site-Directed Mutagenesis 
 
Three RUNX binding sites found within the hclaudin-1 promoter were mutated 
(point-mutation) using the QuikChange XL site-directed mutagenesis kit (Stratagene) 
with the following primers: Cldn1PromMut1F and Cldn1PromMut1R for site 1, 
Cldn1PromMut2F and Cldn1PromMut2R for site 2, Cldn1PromMut3F and 
Cldn1PromMut3R for site 3, and Cldn1PromMut1+2F and Cldn1PromMut1+2R for 
sites 1+2. Reporter plasmid with mutated site 2 was used as template to generate 
reporter plasmid with mutated sites 2+3 using primers set for site 3. Reporter plasmid 
with all sites being mutated were generated using reporter plasmid with mutated sites 
1+2 and primers set for site 3.  
An overview of QuikChange XL site-directed mutagenesis method is 
illustrated in Figure 3.2. Generally, site-directed mutagenesis can be used to create 
point mutations, switch amino acids, delete or insert single or multiple amino acids. 
In this approach, PfuTurbo DNA polymerase, which has a 6-fold higher fidelity in 
DNA synthesis than Taq DNA polymerase was used. It is able to replicate both 
plasmid strands in a supercoiled double-stranded DNA (dsDNA) vector without 
displacing the mutant oligonucleotide primers. Incorporation of the oligonucleotide 
primers generates a mutated plasmid containing staggered nicks. As plasmid DNA 
isolated from almost all of the commonly used E. coli strains (dam+) is methylated, 
the Dpn I endonuclease which is specific for methylated and hemimethylated DNA is 
used to digest the parental DNA template for selection of mutation-containing 
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synthesized DNA. The XL1-Gold ultracompetent cells repair the nicks in the mutated 
plasmid upon transformation of the mutated form of dsDNA into these cells. Being 
endonuclease deficient (endA1) and recombinant deficient (recA), XL10-Gold 
ultracompetent cells greatly improves the quality of plasmid miniprep DNA, and also 
















Figure 3.2: Overview of QuikChange XL site-directed mutagenesis procedure.         




3.2.6.3 Dual-Luciferase Reporter Assay 
 
Transfections into the SNU16 and AGS cell lines were carried out using the 
Lipofectamine 2000 (Invitrogen) and Fugene 6 (Roche) respectively according to the 
manufacturer’s protocol. Fugene 6:DNA amount of 3:1 ratio was used throughout the 
experiment. Upon transfection, SNU16 cells were incubated at 37 ºC for 
approximately 36 hrs. After incubation, 50% of each transfected sample, labeled as 0 
hr time point, were collected and stored as cell pellet at -20ºC. The remaining cells 
were added 3 ng/ml of TGF-β and incubated for 12-18 hrs before cell pellets were 
harvested. These cells were labeled as 12-18 hr time point samples. Similarly, the 
transfected AGS cells were incubated at 37 ºC for approximately 36 hrs before cells 
were harvested. 
All cells were subjected to the luciferase assay using a Dual-Luciferase 
Reporter Assay system (Promega) according to the manufacturer’s protocol. Active 
lysis was carried out for SNU16 cell pellets collected in 1.5 ml eppendorf tubes. AGS 
cells on the other hand were harvested using the passive lysis method. Cells were 
pelleted after cell lysis and 20 µl of cell supernatant was used for the luciferase assay. 
Luciferase assay was carried out as depicted in Figure 3.3 using the Sirius 
luminometer (Berthold Detection System) in triplicates. All firefly luciferase activity 
was normalized by the renilla luciferase activity of the promoterless pRL-SV40 




                                            
 
 
                                             
 
Figure 3.3: Format of the Dual-Luciferase Reporter Assay. The firefly reporter assay 
is initiated by mixing an aliquot of lysate with the Luciferase Assay Reagent II. Upon 
completion of the firefly luciferase assay, the firefly luminescence is quenched and 
Renilla luminescence is simultaneously activated by adding Stop & Glo Reagent to 




100µl of Luciferase Assay 
Reagent II. 
Transfer 20µl of cell lysate 
in lysis buffer. Mix.  
 Measure firefly luciferase activity. 
100µl of Stop & Glo 
reagent. 
Measure Renilla luciferase activity. 
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3.2.7 Generation of Stable Cell Line 
 
3.2.7.1 Plasmids and Stable Cell Line 
 
The AS RUNX3 plasmid construct was generated by inverting the RUNX3 cDNA 
(RUNX3 coding region + 5’ and 3’ UTR) (appendix 5), followed by cloning into the 
pEFBos/Neo vector between the XbaI site by blunt end ligation (generated and 
provided by Dr. Suk Chul Bae from Chungbuk National University, South Korea). 
This expression construct was transfected into the SNU16 cells to generate AS 
SNU16 stable cell line. RUNX3 cDNA was also cloned into the Flag-tagged 
pcDNA3/Neo vector (Invitrogen). This expression construct was transfected into the 
SNU16 cells to generate SNU16 stable cell line harboring exogenous RUNX3.  
Mouse claudin-1 ORF (666 bp) (appendix 6) was amplified from pBIG-
mClaudin-1/Myc (kindly provided by Dr. Eveline Schneeberger, University of 
Harvard, USA) using the mclaudin-1 ORF/Myc-F and mclaudin-1 ORF/Myc-R 
primers. The amplified product was cloned into the pcDNA3.1/Hygro vector 
(Invitrogen) between the EcoRV and NotI sites. The expression construct and 
pcDNA3.1/Hygro vector alone was transfected seperately into GIF5 and GIF14 cells. 
hclaudin-1 ORF (636 bp) (appendix 7) was inverted and cloned into 
pcDNA3.1/Hygro between the EcoRV and NotI sites using the AShclaudin-1 ORF-F 
and AShclaudin-1 ORF-R primers. This expression construct and the 
pcDNA3.1/Hygro vector alone were transfected separately into the SNU16 cells. 
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Transfections into SNU16 cells were carried out using Lipofectamine 2000 
(Invitrogen), whereas transfections into GIF5 and GIF14 cells were carried out using 
Fugene 6 (Roche).  
 
3.2.7.2 Stable Transfection and Stable Cloning 
 
Transfection into the SNU16 cell line was carried out using Lipofectamine 2000 
(Invitrogen), whereas transfection into the AGS, GIF5 and GIF14 cell lines were 
carried out using Fugene 6 reagent (Roche). All transfections were carried out in 6-
well plates. Cells were allowed to grow for 48 hrs, followed by the addition of 
antibiotic for selection of transfected cells. 0.6 mg/ml of Neomycin or 125 µg/ml of 
Hygromycin was used depending on the antibiotic selection of the vector used. Cell 
growth was monitored in the presence of antibiotic.  
For attachment cells like AGS, GIF5 and GIF14, dead floating cells were 
discarded and fresh medium was changed every 2-3 days to allow attached cells to 
grow till at least 50% confluency. Cells were then trypsinized and well-suspended 
cells were subcultured into multiple 10 cm dish in dilutions of 1:500, 1:1000 and 
1:2000. Dispersed single cells were allowed to attach on dish and grow. Expansion of 
attached cell colonies was monitored in the presence of antibiotic. When cell colonies 
grow to approximately 2-3 mm in size, cells were trypsinized in cloning ring and 
subcultured to 12-well plates. Cells that continue to grow in the presence of antibiotic 
were again subcultured to 6-well plates and allowed to grow to approximately 90% 
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confluency. Cells were harvested and divided into three portions: for protein 
extraction, subculturing and storage purposes. Presence of selected genes in stable 
clones was determined using western blotting. For SNU16 suspension cells, selection 
of stable clones was carried out in 96-well plates using the serial dilution method. 
Wells that contained 1-3 cells that continued to grow in the presence of antibiotic 
were monitored and new medium was added every 2-3 days. Expended cells were 
subcultured to 24-well plates, followed by 12-well and 6-well plates. Cells were 
harvested and divided as mentioned above. Positive stable clones were determined 
through western blotting.   
 
3.2.8 Xenografts in Nude Mice 
 
Each of GIF5+pcDNA3.1 and GIF5+mclaudin-1, GIF14+pcDNA3.1 and 
GIF14+mclaudin-1 as well as SNU16+pcDNA3.1 and SNU16+AShclaudin-1 stable 
cell lines (5 x 106 cells respectively in PBS) were injected subcutaneously into the 
flanks and back of 10 approximately 2-mth old female nude mice using a 27 ½ gauge 
needle (Figure 3.4). When the tumors grow to approximately 1 cm of size, they were 
cut out and weight (gm) was measured. Tumors were kept in 80% ethanol for long 














Figure 3.4: Nude mice assay in Runx3-/- GIF and SNU16 cell lines. (A) Rescue 
experiment to observe if exogenous expression of mclaudin-1 in Runx3-/- GIF cells 
reduces tumorigenecity in nude mice. (B) Experiment to observe if knock-down of 
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3.2.9 Collection and Processing of Mouse and Human Tissue Samples 
 
3.2.9.1 Fixing, Processing and Embedding of Mouse Stomach 
 
Freshly dissected neonatal 0 day mice stomach was fixed in 4% paraformaldehyde 
(PFA) for approximately 2 hrs at 4ºC, briefly rinsed with dH2O, followed by 70% 
ethanol overnight at RT. The specimen was then transferred to the tissue processor 
(Tissue Tek Citabel 2000) for dehydration and processing. The specimen was 
subjected to dehydration in a series of ethanol followed by xylene and paraffin as the 
following: 1X 80% ethanol for 1 hr, 1X 90% ethanol for 1 hr, 2X 100% ethanol at 1 
hr each, 2X xylene at 1 hr each, 1X xylene + paraffin (1:1) for 2 hrs, 1X paraffin for 1 
hr followed by a final immersion in paraffin until the specimen was taken out for 
embedding. The processed specimen was taken out and immediately embedded on a 
paraffin block which was then left to solidify. Paraffin blocks were kept at RT until 
ready to be sectioned.    
 
3.2.9.2 Human Gastric Cancer Specimens  
 
52 surgically resected gastric adenocarcinoma samples and their corresponding non-
cancerous tissues were obtained from the Department of Pathology and Surgery, 
National University of Singapore under a protocol approved by the Institutional 
Review Board. According to Lauren’s classification for gastric adenocarcinoma, there 
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were 29 differentiated/ intestinal type of gastric adenocarcinoma, and 23 diffuse type 
of gastric adenocarcinoma. 
  
3.2.10 Microscopy Technique 
 
3.2.10.1 Immunocytochemistry (IF) 
 
GIF cells grown on cover slips in 6-well plates that reached approximately 90% 
confluency were fixed with 4% PFA for 10 min at RT. Cells were rinsed briefly with 
PBS, followed by permeabilization with 0.1% Triton X-100 for 10 min at RT, and 
rehydration with PBS. After blocking with hydrogen peroxide for 5 min at RT, cells 
were incubated with 1:100 of rabbit anti-claudin-1 diluted in antibody diluent for 1 hr 
at RT. Cells were washed three times for 5 min each with PBST at RT. Biotinylated 
anti-rabbit IgG (1:200 dilution) and fluorescein avidin D (1:2000 dilution) were used 
as secondary and tertiary antibody respectively and incubated for 1 hr each at room 
temperature. Cells were washed three times for 5 min each with PBST at RT in 
between the secondary and tertiary antibodies. Slides were counterstained with DAPI 
(D8417; Sigma) diluted to 0.2 µg/ml in PBS for 3 min at RT. Slides were washed 
three times with PBS for 3 min each at RT. Mounted slides were subsequently used 
for immunofluorescence imaging with Zeiss microscope (Axioplan 2 imaging 




3.2.10.2 Immunohistochemistry (IHC) 
 
Mouse tissues embedded in paraffin blocks were sectioned into 5 µm using a 
microtome (Leica RN2255) to obtain a series of approximately 10 continuous 
sections. Sections were placed on the surface of 80% Ethanol to facilitate separation 
of serial sections into single section. Each serial section was transfered to water bath 
at approximately 42ºC and left for few seconds for rehydation and fished out and 
displayed onto the poly-L-lysine coated slides. Slides were left on heating block set to 
37ºC for approximately 1 hr until sections were dry. Deparaffinization was carried out 
in xylene followed by rehydration of specimen in ethanol. Deparaffinized tissues 
were incubated at 96°C for 40 min with antigen retrieval solution (S1700; Dako) and 
cooled down for 30 min at RT. After blocking with hydrogen peroxidase for 5 min, 
the specimens were incubated with rabbit anti-Claudin-1 (1:100 dilution) for 1 hr at 
RT, followed by three time washing for 5 min each with PBST at RT. Secondary 
antibody and chromogen-substrate for visualization were added according to the 
instructions given by the EnVision+ system (DAB) kit. After development with 
diaminobenzedine, the sections were counterstained with hematoxylin, dehydrated 
and mounted with coverslips.  
52 human tissues were fixed with 10% neutral-buffered formalin, embedded 
in paraffin, and serially sectioned at 4 µm. After routine deparaffinization and 
rehydration, specimen was treated at 96°C for 40 min with antigen retrieval solution. 
Specimens were cool down for 30 min at room temperature. After blocking with 
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hydrogen peroxidase, the specimens were incubated with rabbit anti-Claudin-1 (1:100 
dilution) and mouse anti-RUNX3 (1 μg/ml, R3-6E9) (97) for 1 hr at RT. The 
EnVision+ system (DAB) kit was used for visualization. After development with 
diaminobenzedine, the sections were counterstained with hematoxylin, dehydrated 
and mounted with coverslips. Cases showing RUNX3 expression in the nucleus were 
counted as positive. Cases with no expression or showing RUNX3 expression in the 
cytoplasm were counted as negative.   
 
3.2.11 Electrophoresis Mobility Shift Assay (EMSA)  
 
EMSA was carried out according to the manufacturer’s protocol provided by the 
LightShift Chemiluminescent EMSA kit and the Chemiluminescent Nucleic Acid 
Detection Module. Labeled probes were prepared by annealing six pairs of 5’ 
biotinylated oligomers with nonlabeled complementary oligomers; unlabeled 
competitor probes were prepared by annealing six pairs of two unlabeled 
complementary oligomers in annealing buffer comprising of 20 mM Tris (pH7.5), 50 
mM NaCl and 10 mM MgCl2.  Complementary oligomers were denatured at 95°C for 
5 min and left to cool down at room temperature to enable annealing to happen. First 
set of probes cover the first and second RUNX binding sites, whereas the second set 
of probes cover the third RUNX binding site. Four pairs of oligonucleotides that were 
used as probes for site 1 and 2 include WT-WT, WT-MT, MT-WT and MT-MT. 
Probes for site three include WT and MT. A final concentration of 30 fmol of labeled 
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probes and 4 pmol of unlabeled probes were used for the binding reactions in the 
presence of 1 µg/µl of poly (dI-dC) and 1x binding buffer. 200 ng of anti-RUNX3 
(R3-5G4) were added to the control reaction to check the specificity of binding.           
 Briefly, binding reactions were prepared on ice with the addition of distilled 
water, 10X binding buffer, 1 µg/µl of poly (dI-dC), unlabeled probe and protein 
extract (293T cells with or without exogenous RUNX3) in sequence. The binding 
reaction was performed at RT for 20 min before the biotin-labeled probe was added. 
Loading buffer was mixed with the binding reactions and loaded into 0.5X TBE gel. 
Gel electrophoresis was carried out at 100 V until the bromophenol blue dye migrated 
¾ down the length of the gel. DNA on gel was transferred to nylon membrane in ice-
cold 0.5X TBE buffer at 100 V for 30 min. Cross-linking of DNA to membrane was 
performed twice for 1 min each at 120 mJ/cm2 using a UV-cross-linker. Nylon 
membrane was then incubated with blocking buffer for 15 min with gentle shaking, 
followed by incubation with streptavidin-horseradish peroxidase conjugate for 15 min 
with gentle shaking. Membrane was washed four times for 5 min each with 1X wash 
solution with gentle shaking. Substrate equilibration buffer was added for 5 min with 
gentle shaking. Finally, membrane that has been removed from the substrate 
equilibration buffer was added the mixture of luminal/ enhancer solution and stable 






3.2.12 Chromation Immunoprecipitation (ChIP)  
 
Chromatin immunoprecipitation (ChIP) was performed according to the 
manufacturer’s protocol provided by the EZ ChIP Chromatin Immunoprecipitation kit. 
Crosslinking of histones to DNA in formaldehyde was carried out for 5 min at 37°C. 
Sheering of DNA was done by sonication using 8 sets of 12-second pulses with 30% 
of maximum power on a sonicator (Sonifier 150; Branson). 5 µg of anti-RUNX3 (R3-
6E9) was used to immunoprecipitate endogenous RUNX3 from the SNU16 cells. 
Protein G Agarose was used to collect the antibody/ histone complex. As control, 5 
µg of mouse normal IgG (sc-2025; Sigma) was used in a separate reaction. Washing 
of protein G agarose/ antibody/ chromatin complex was carried out followed by 
elution in elution buffer (1% SDS, 0.1 M NaHCO3).  
 The chromatin complex was reverse cross-linked and DNA was recovered 
by phenol/ chloroform extraction and ethanol precipitation. Primers Cldn1CHIP-2F 
and Cldn1CHIP-2R which are specific to the human claudin-1 promoter were used to 
amplify the DNA fragment comprising of all three RUNX binding sites. Primers FOR 
and REV specific for the GAPDH promoter were used to perform PCR on the pull-
down DNA, acting as a negative control. PCR for claudin-1 was carried out at 94ºC 
for 5 min and for 32, 35 or 37 cycles each of 94ºC for 30 sec, 58ºC for 30 sec, 72ºC 
for 30 sec and final cycle of 72ºC for 10 min. PCR for GAPDH was carried out at 
94ºC for 5 min and for 32 cycles each of 94ºC for 30 sec, 60ºC for 30 sec, 72ºC for 30 
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sec and final cycle of 72ºC for 10 min. PCR amplification product was visualized on 



























4.1.1 Expression of TJ Proteins in Mouse Gastric Epithelial Cells  
 
RUNX3 was found to be a strong candidate for gastric cancer tumor suppressor as loss 
of expression or mislocalization of RUNX3 protein are associated with gastric 
carcinogenesis (23, 97). In a previous report, Runx3-/- gastric epithelial cells were 
shown to attach weakly to each other, suggesting a loss of Runx3 function may be 
responsible for the reduction of cell-cell contact and polarity (95). To investigate 
whether RUNX3 plays a role in the regulation of cell-cell contact and polarity, 
Western blot analysis was performed on a series of mouse embryonic gastric 
epithelial cells (GIF cells), namely the GIF5 and GIF14 Runx3-null cells and the 
Runx3 expressing GIF9 and GIF13 cells, to examine the relationship between Runx3 
expression and expression of proteins involved in cell-cell contact. 
The AJ and TJ proteins are known to function in the maintenance of cell-cell 
contact and polarity. Thus the expression level of E-cadherin, an AJ protein known to 
play a role in gastric carcinogenesis and TJ proteins including claudin-1, claudin-2, 
claudin-3, claudin-4, claudin-7, claudin-11, claudin-16, ZO-1, ZO-2, ZO-3 and 
occludin was examined using these cell lines.  
72 
 
 Interestingly, the TJ  proteins, claudin-1, claudin-3, ZO-3 and occludin were 
found to be expressed in high abundance in Runx3 expressing GIF9 and GIF13 cells, 
whereas none or very low level were detected in Runx3-null GIF5 and GIF14 cells 
(Fig. 4.1). These results suggest that presence of Runx3 has a direct or indirect effect 
on the expression of claudin-1, claudin-3, ZO-3 and occludin in the mouse embryonic 
gastric epithelial cells. In contrast, the expression of E-cadherin was not affected by 
the presence or absence of Runx3. Claudin-2, -4, -7, -11 and -16 however were not 












Figure 4.1: Western blot analysis of tight junction (TJ) and adhesion junction (AJ) 
proteins in Runx3-/- and Runx3+/+ mouse gastric epithelial GIF cell lines. claudin-1, 
claudin-3, ZO-3 and occludin were expressed in high abundance in Runx3 expressing 
GIF9 and GIF13 cells, whereas none or very low level were detected in Runx3-null 
GIF5 and GIF 14 cells. Claudin-2, claudin-4, claudin-7, claudin-11 and claudin-16 




4.1.2 TJ Proteins and TGF-β Pathway 
 
RUNX3 functions as a tumor suppressor under the TGF-β pathway. To observe if the 
TJ proteins as well as E-cadherin tested in section 4.1 were regulated downstream of 
RUNX3, the expression level of these proteins in the presence and absence of TGF-β 
were observed. As Runx3 expressing GIF cell lines expressed relatively low level of 
Runx3, it was not the best cell line to be used for this study. For this purpose, the 
SNU16 cell line which is a human gastric cancer cell line that expresses relatively 
high level of RUNX3 and responses to the treatment of TGF-β was used. SNU16 cell 
lysate was collected at 0 hr before addition of TGF-β and at 6, 12 and 24 hr after 
addition of TGF-β, followed by Western blot analysis with the antibody against the 
respective TJ proteins (Fig. 4.2).  
  From the series of TJ and AJ proteins tested, only claudin-1 showed 
responsiveness towards TGF-β, whereby its expression increased in a time dependent 
manner upon addition of TGF-β. This indicates that TGF-β is involved in the 
induction of claudin-1 expression in SNU16 gastric epithelial cells. This regulation 
pattern however was not observed in other TJ and AJ proteins. Hence, claudin-1 was 
selected for further analysis whereas claudin-3, ZO-3 and occludin were omitted even 
though their expression showed a positive correlation with Runx3 in mouse 





4.1.3 RUNX3 and claudin-1 in TGF- β Pathway 
 
To further confirm that claudin-1 expression is regulated by TGF-β, experiment in 
(Fig. 4.3A) was carried out. SNU16 cells that were treated with TGF-β for 24 hr 
showed a higher claudin-1 expression level as compared to the untreated one (Lane 1 
& 2). When the TGF-β inhibitor was added to SNU16 cells in the presence of TGF-β, 
the induction of claudin-1 expression greatly diminished (Lane 3). This clearly shows 
that the TGF-β signaling pathway is involved in the regulation of claudin-1 
expression in the SNU16 cell line.  
To observe if RUNX3 is involved in the regulation of claudin-1 under the 
TGF-β pathway, the expression of claudin-1 was compared between the SNU16 cell 
line and the AS SNU16 cell line, in which RUNX3 was knocked-down by using the 
antisense DNA against RUNX3 (Fig. 4.3B). Both RT-PCR and Western blot analysis 
showed a time-dependent increased of claudin-1 expression in SNU16 cell line upon 
treatment by TGF-β. This pattern of claudin-1 expression however was not observed 
in the AS SNU16 cell line. This shows that RUNX3 is necessary for the regulation of 













Figure 4.2: TGF-β treatment and expression of tight junction and adhesion junction 
proteins. SNU16 cell lysates were collected at 0 hr before treatment with TGF-β and 
at 6, 12 and 24 hr upon treatment with TGF-β. Western blot analysis was carried out 
using antibodies against the respective tight junction and adhesion junction proteins. 
claudin-1 expression increased in response to TGF-β, indicating that claudin-1 
expression is regulated by the TGF-β signaling pathway. claudin-2, claudin-11 and 
























Figure 4.3: Regulation of claudin-1 by TGF-β. (A) Induction of claudin-1 by TGF-β 
was highly reduced in the presence of TGF-β inhibitor, confirming the involvement 
of TGF-β signaling pathway in the regulation of claudin-1 expression. (B) RT-PCR 
and Western blot analysis showing claudin-1 expression in the presence and absence 
of RUNX3. AS SNU16 is a RUNX3-knocked-down SNU16 cell line using the 
antisense DNA against RUNX3. Reduced level of RUNX3 was confirmed by Western 
blot analysis. The TGF-β dependent expression of claudin-1 was greatly reduced 
when majority of RUNX3 was knocked-down, indicating the involvement of RUNX3 















Figure 4.4: Quantitative RT-PCR analysis of claudin-1 expression upon induction by 
RUNX3 in SNU16 cell line. Stable SNU16 cell line expressing exogenous RUNX3 
was assigned SNU16+FlagRUNX3 (black bars). Basal expression level of RUNX3 
and claudin-1 in SNU16 were adjusted to 1 (white bars) for comparison purposes. 
Claudin-1 expression was increased by approximately 2.7 folds in the presence of 
exogenous RUNX3, indicating that RUNX3 is involved in the induction and 




4.1.4 claudin-1 Expression in Mouse Gastric Epithelial Cells 
 
The expression pattern of claudin-1 was further confirmed by immunofluorescence 
staining using the Runx3+/+ and Runx3-/- GIF cell lines. Runx3+/+ GIF9 and GIF13 
cell lines were positively stained by claudin-1, whereas Runx3-/- GIF5 and GIF14 cell 
lines were either not stained, or stained at very low level by claudin-1 (Fig. 4.5A). 










Figure 4.5: Immunodetection of claudin-1 in mouse gastric epithelial cells and tissue 
samples. (A) Immunofluorescence analysis of claudin-1 in Runx3-/- and Runx3+/+ 
GIF cell lines. Runx3+/+ cells showed clear claudin-1 staining at cell-cell boundaries. 
Runx3-/- GIF cells showed none or very low level of claudin-1 expression. Scale bar, 
50 µm. (B) Immunohistochemistry analysis of neonatal 0 day mice stomach. Left and 
middle panels represent stomach sections from wild-type mice; right panel represents 




Immunohistochemistry staining was also performed on sections of wt and 
Runx3 knock-out mouse gastric epithelial tissues which were embedded into paraffin 
blocks. Results showed that claudin-1 stained positively on the surface membrane of 
wt mouse gastric epithelial cells. Runx3 knock-out gastric epithelial cells on the other 
hand show greatly diminished level of claudin-1 expression (Fig. 4.5B). These results 
collectively show that claudin-1 expression is positively correlated to the expression 
of Runx3 in mouse gastric epithelial model.  
 
4.1.5 claudin-1 Promoter Assay 
 
Results from section 4.13 shows that RUNX3 mediates induction of claudin-1 
transcription. In order to examine the direct involvement of RUNX3 in the regulation 
of claudin-1 expression, a human claudin-1 promoter was examined. The constructed 
promoter contains three putative RUNX binding elements (Fig. 4.6A). The proposed 
consensus sequence for RUNX binding element was 5’-PuACCPuCA-3’, or in the 
reverse orientation, 5’-TG(T/G)GGT-3’, with 5’-AACCACA-3’ being the regular 
type of sequence found in most bona fide RUNX target promoters (212). The second 
and third RUNX binding consensus, which happened to be the regular type, were 
found to be highly conserved in the mouse and human claudin-1 promoter (Fig. 4.6B). 
Seven types of luciferase reporter plasmids were constructed, each containing one 
(M1, M2 & M3), two (M1+2, M1+3, M2+3) or three (M1+2+3) mutant binding 
elements, upstream of the luciferase gene. All reporter activity was normalized 
against the luciferase activity expressed by the promoterless pRL-SV40 vector.  
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Reporter assay was first performed using the SNU16 cell line. Figure 4.7 showed that 
the reporter activity of WT promoter increased in a dose dependent manner, both 
before and after the addition of TGF-β. In the AGS cell line in which RUNX3 is not 
expressed, the reporter activity of WT promoter increased in consistent with the 
addition of RUNX3 and was RUNX3-dose-dependent (Fig.4.8A). In Figure 4.8B, the 
reporter activity increased for about 1.7 folds when Smad3 and Smad4 were added as 
compared to control. This was possible as there were six Smad binding elements 
found within the human claudin-1 promoter downstream of the third RUNX binding 
site and this verifies the proper function of the promoter. The promoter activity 
increased by another 2.2 folds when RUNX3 was added in addition to Smad3 and 
Smad4, resulting in an approximately 4 folds increase of promoter activity compared 
to the control.  
The reporter activity of wild type plasmid was also significantly higher than 
that of any reporter plasmid containing one or more mutant elements. When all three 
RUNX binding elements were mutated, the reporter activity was abolished (Fig. 
4.8B). These results collectively indicate that RUNX3 induces claudin-1 expression in 





















Figure 4.6: hclaudin-1 promoter. (A) Schematic diagram of the hclaudin-1 promoter, 
1500 bp upstream of the transcriptional start site. Three RUNX consensus binding 
sequence, with their respective mutants were highlighted in red. Mutants were 
generated using the site-directed mutagenesis method. (B) Schematic diagram 
showing conservation of the second and third RUNX binding sites in the human and 





CTGTTTTTACTAAATCCATAGAAGCCTCTC TTTC CACCGTACTCACACCACAGACAAAAT  
AGCAGTTGGAAAAACATTTCAATGATTCCTAACCACAA  

















Figure 4.7:  hclaudin-1 reporter assay in SNU16 cell line. hclaudin-1 promoter 
activity was up-regulated by the expression of RUNX3 in a RUNX3-dose dependent 
manner. 0 hr represents sample before addition of TGF-β, 12 hr represents sample at 

























































Figure 4.8: hclaudin-1 reporter assay in AGS cell line. (A) Up-regulation of promoter 
activity was RUNX3-dose-dependent. (B) WT represents wild-type reporter construct. 
M1, M2 and M3 represent reporter constructs with single mutant at first, second and 
third RUNX binding sites. M1+2, M1+3, M2+3 and M1+2+3 represent reporter 
constructs with compound mutants at RUNX binding sites. As compared to the WT 
promoter, single and compound mutants show significant reduction of promoter 
activity in the presence of RUNX3 and Smads. Two tailed Student’s t test: (*) p<0.05; 
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4.1.6 Electrophoretic Mobility Shift Assay (EMSA) 
 
To investigate the possibility of direct interaction between the putative binding 
elements in the claudin-1 promoter and RUNX3, EMSA was performed using double-
stranded DNA probes containing either the wild type or mutant sequences of the 
binding elements (Fig. 4.9). Protein extracts were obtained from 293T cells which do 
not contain endogenous RUNX3, and 293T cells exogenously expressing RUNX3. 
IgC-alpha promoter region contains three RUNX binding sites, thus were used as the 
control probe in this assay (Lane 1-3). Four pairs of probes covering first and second 
RUNX binding elements, which contain both wild type (WT-WT), one wild type and 
one mutant (WT-MT; MT-WT) or both mutant (MT-MT), and 2 probes covering 
third RUNX binding element (WT and MT) were used.  
A band corresponding to RUNX3 binding to probe containing two wild type 
RUNX binding elements was observed as shown in lane 6. Addition of unlabelled 
wild type competitor probe blocked this association (Lane 7), but not for unlabelled 
competitor probe containing both mutated RUNX binding sites (Lane 8). These 
results were likewise observed for probes with one wild type and one mutant RUNX 
binding sites (WT-MT and MT-WT) (Lane 16-19). These results collectively show 
that RUNX3 binds to the first and second RUNX binding sites in the claudin-1 
promoter. When either one of these RUNX binding sites was being mutated, the 
binding affinity of RUNX3 to the probe became weaker, as shown by the weaker 
bands in lane 16 and 18 as compared to lane 6. RUNX3 also binds to the third RUNX 
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binding site, with a stronger affinity, as shown by the stronger bands in Lane 11 & 13. 
To confirm the specificity of these shifts, the anti-RUNX3 (R3-5G4) monoclonal 
antibody which is specific for RUNX3 was added. A supershifted band was observed, 
confirming that RUNX3 protein was present in the DNA-protein complexes (Lane 
20). These observations clearly show the direct binding of RUNX3 to claudin-1 






















Figure 4.9: Electrophoretic Mobility Shift Assay (EMSA). Protein extract was 
obtained from 293T cells in the presence and absence of exogenous RUNX3. IgCα 
WT probe which contains RUNX binding sites acts as positive control. Both biotin-
labeled and unlabeled probes of 35 mers were used. First set of probes contain either 
wild-type or mutated forms of first and second RUNX binding sites (WT-WT, WT-MT, 
MT-WT, MT-MT); second set of probes contain only wild-type or mutated form of 
third RUNX binding site (WT, MT). Results showed that RUNX3 binds to all 3 
putative RUNX binding sites on hclaudin-1 promoter, with third RUNX binding site 




4.1.7 Chromatin Immunoprecipitation (ChIP)   
 
To observe if RUNX3 also binds to claudin-1 in vivo, ChIP assay was carried out 
using the SNU16 cells containing endogenous RUNX3. As shown in Figure 4.10, the 
anti-RUNX3 (R3-6E9) monoclonal antibody was able to successfully pull down 
claudin-1 promoter region. Upon TGF-β treatment, RUNX3 localized in the 
cytoplasm is translocated into the nucleus. Hence, more RUNX3 is available to bind 
to the claudin-1 promoter, resulting in the increase in immunoprecipitated claudin-1, 
as shown by the higher intensity of the PCR product. Quantitation of the ChIP band  
was done by increasing cycles of PCR. PCR using the GAPDH primers and pull-
down by a normal mouse IgG acted as negative controls, to show that the pulled-
down chromatins by the RUNX3 antibody was specific. Thus, the results show that 
RUNX3 binds to the claudin-1 promoter in vivo and claudin-1 is a direct target of 
























Figure 4.10: Chromatin Immunoprecipitation (ChIP) assay. PCR results with primers 
specific to hclaudin-1 promoter indicates the specificity of pull-down product as well 
as specificity of antibody used. Figures on the right panel indicate number of PCR 
cycles. PCR for input is done using primers specific to hclaudin-1 promoter. A 
smaller band detected below the claudin-1 band in the 6E9 precipitates is a result of 










4.1.8 Nude Mice Assay 
 
4.1.8.1 Restoration of claudin-1 Expression and Its Tumor Suppressive Effect  
 
As shown in Fig. 4.1 and Fig. 4.5A, Runx3-/- GIF5 cell line does not express claudin-1 
whereas Runx3-/- GIF14 cell line expresses very low level of claudin-1. A previous 
publication showed that GIF cells from Runx3-/- mice were tumorigenic in nude mice, 
whereas GIF cells from Runx3+/+ mice were not (23). To check if claudin-1 acts as a 
tumor suppressor in gastric epithelial cells, GIF5 and GIF14 stable cell lines 
expressing exogenous claudin-1 in the pcDNA3.1 vector were generated. 
Interestingly, restoration of exogenous claudin-1 in both GIF5 and GIF14 cells 
greatly suppress tumorigenicity in nude mice, and the tumor suppressive effect was 
correlated well to the level of claudin-1 expression in these stable cell lines. The 
number of tumors was lower when the level of exogenously expressed claudin-1 was 
higher (Fig. 4.11 & 4.12). These results show that restoration of claudin-1 expression 
contributes to the tumor suppressive effect in the tumorigenic mouse gastric epithelial 
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Figure 4.11: Nude mice assay in Runx3-/- GIF5 cell line. GIF5 stable cell lines 
expressing exogenous mclaudin-1 (clone 1 and 2), and GIF5 control cell line stably 
expressing pcDNA3.1 were used. GIF5 stable cell lines expressing mclaudin-1 highly 
reduced tumorigenicity in nude mice as compared to control GIF5 cells, indicating 
the possible role of claudin-1 as a tumor suppressor, functioning as a target of RUNX3.  
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Figure 4.12: Nude mice assay in Runx3-/- GIF14 cell line. GIF14 stable cell lines 
expressing exogenous mclaudin-1 (clone 2 and 3), and GIF14 control cell line stably 
expressing pcDNA3.1 were used. GIF14 stable cell lines expressing mclaudin-1 
highly reduced tumorigenicity in nude mice as compared to control GIF14 cells, 
indicating the possible role of claudin-1 as a tumor suppressor, functioning as a target 
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Figure 4.13: Nude mice assay in the SNU16 human gastric cancer cells. SNU16 
stable cell lines whereby endogenous claudin-1 was stably knocked-down (clone 8 
and 9), and SNU16 control cell line stably expressing pCDNA3.1 were used. Knock-
down of hclaudin-1 in SNU16 stable cell lines enhances tumorigenicity as compared 
to the control SNU16 cells, supporting the role of claudin-1 as a tumor suppressor. 




4.1.8.2 Reduced claudin-1 Expression Enhances Tumorigenicity 
 
The effect of reduction of claudin-1 expression on tumorigenicity was then examined. 
SNU16 stable cell line with reduced level of claudin-1 was generated using the 
antisense DNA against claudin-1. Consistence with the observations in GIF5 and 
GIF14, reduction of claudin-1 enhanced tumorigenicity in nude mice (Fig. 4.13). 
These observations collectively show that claudin-1 has the tumor suppressive 
property in gastric epithelial cells, whereby its restoration helps to lower the 
incidence of tumor formation.   
 
4.1.9 Claudin-1 and RUNX3 Expression in Human Gastric Cancer Samples 
 
A total of 52 gastric cancer samples were analyzed for the expression of RUNX3 and 
claudin-1. Figure 4.14 shows the expression pattern of RUNX3 and claudin-1 in 
normal human adult gastric mucosa. Both RUNX3 and claudin-1 are expressed most 
strongly in chief cells and surface epithelial cells and to a lesser degree in parietal 
cells. RUNX3 stains the nucleus whereas claudin-1 stains at cell-cell boundaries and 
in the cytoplasm.  
Table 4.1 and 4.2 show a summary of RUNX3 and claudin-1 expression in the 
52 gastric cancer cases whereby 29 samples (55.8%) were differentiated type whereas 
23 samples (44.2%) were diffuse (undifferentiated) type. RUNX3 expression that was 
detected in nucleus was scored as positive, whereas no expression or those in the 
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cytoplasm was scored as negative. Base on the results, these samples were 
categorized into three groups according to the expression of RUNX3 and claudin-1, 
whereby 15 samples (28.8%) expressed both RUNX3 and claudin-1 (Fig. 4.15A); 17 
samples (32.7%) neither express RUNX3 nor claudin-1 (Fig. 4.15B); and 20 samples 
(38.5%) expressed only claudin-1 but not RUNX3 (Fig. 4.16).  
RUNX3 was only expressed in a total of 15 samples (28.8%) and it was 
interesting to observe that claudin-1 was also expressed in all these cases. This 
suggests that when RUNX3 was present, claudin-1 was also induced. Besides, it was 
also interesting to note that all 32.7% of samples that stain negatively for claudin-1 
was in fact in the subset of RUNX3 negative cases, indicating that loss of RUNX3 
expression also inhibited the expression of claudin-1. These results collectively show 
that expression of claudin-1 and RUNX3 is correlated in approximately 61.5% 
(28.8% + 32.7%) of the gastric cancer cases.  
The third group of results showed that claudin-1 was expressed in the absence 
of RUNX3 (38.5%). This suggested that claudin-1 was also regulated by factors other 
than RUNX3. However, as shown in Figure 4.16, in samples that RUNX3 was absent, 
claudin-1 expression level also appeared to be lower as compared to samples with 
RUNX3 expression. This observation was consistent throughout the three types of 
tissues that were analyzed, namely the poorly-differentiated, the well-differentiated 
and the diffuse type of gastric cancer. This suggested that RUNX3 plays a crucial role 
























Figure 4.14: Expression pattern of claudin-1 and RUNX3 in normal human gastric 
sample. Both RUNX3 and claudin-1 are expressed most strongly in chief cells and 
surface epithelial cells and to a lesser degree in parietal cells. RUNX3 stains the 
nucleus whereas claudin-1 stains at cell-cell boundaries and in the cytoplasm.  
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Figure 4.15: RUNX3 and claudin-1 expression pattern in differentiated and diffuse 
type of human gastric cancers. (A) 15 samples (28.8%) expressed both RUNX3 and 
claudin-1. (B) 17 samples (32.7%) did not express both RUNX3 and claudin-1. Scale 



















Figure 4.16: Staining pattern of claudin-1 in the RUNX3 positive and negative cases 
from the poorly-differentiated, well-differentiated and diffuse type of gastric cancer. 
A total of 38.5% cases express only claudin-1 but not RUNX3. When RUNX3 was 
absent, claudin-1 expression also appeared to be lower as compared to those with 
RUNX3 expression. This suggested that claudin-1 expression is RUNX3 dependent. 








Table 4.1: RUNX3 vs claudin-1 expression in 52 gastric cancers 
 
  Sample Claudin-1 RUNX3   Sample Claudin-1 RUNX3 
U GT24 N N U GT53 P P 
U GT25 N N D GT54 P N 
U GT26 P P D GT55 P N 
U GT27-1 N N U GT57 P P 
U GT27-2 N N D GT61 N N 
U GT30 P N U GT63 P N 
U GT31 N N D GT64 N N 
U GT32 N N U GT67 P N 
U GT34 N N D GT69 N N 
D GT37 N N D GT71 N N 
D GT39 N N D GT73 P N 
D GT40 P P U GT76 P P 
D GT42 P N U G10 P P 
D GT44 N N D G54 P N 
U G00104 P N D G55 P N 
U G00143 P P D G84 P N 
U G01032 P P D G111 P N 
U G01058 P N D G118 P N 
D G02005 P N D G136 P P 
D G04142 P N D G148 P N 
D G04202 P P D G0102 P P 
U G04197 P P D G0155 P N 
D GT2 N N U G0158 P P 
U GT4 N N D G0182 P N 
D GT51 N N U G0204 P P 
D GT52 P P D G0250 P N 
P = positive; N = negative 
# U = Diffuse; D = Differentiated 

























(n=29) 24 (83.0)   5 (17.0)  9 (31.0) 20 (69.0) 
Diffuse (n=23) 13 (56.5) 10 (43.5)  8 (35.0) 15 (65.0) 





















4.2  Discussions  
 
Due to the lack of cell-cell contact and polarity in Runx3-/- mice, the possible role of 
RUNX3 in this function was investigated by screening several TJ proteins and the E-
cadherin AJ protein to check their correlation with RUNX3. E-cadherin AJ molecule 
was included in the screen as dysfunction of E-cadherin has been a well-known cause 
of gastric carcinogenesis (213, 214). Results showed that RUNX3 transcriptionally 
regulated the expression of claudin-1. Claudin-1 was also shown to have tumor 
suppressive activity. Therefore, a part of tumor suppressor activity of RUNX3 is likely 
to be to positively regulate the expression of claudin-1.   
Various claudin genes including claudin-1 have been reported to play a role in 
gastric cancer. Recently, it was reported that diffuse type of gastric carcinomas shows 
lack of claudin-1 and claudin-4 expression (169). A tissue microarray study shows a 
lower expression of claudin-1, -3, -4 and ZO-1 in diffuse type of gastric cancer (165). 
Study by Lee et al. also observed that loss of claudin-4 promotes the advancement of 
gastric adenocarcinoma (155).  
  Quantitative RT-PCR method also revealed the down-regulation of claudin-18 
in intestinal type of gastric cancer, which was postulated to be an early event in 
gastric carcinogenesis (166). Claudin-23 on the other hand, was found to be down-
regulated in the intestinal type of gastric cancer (167). All these genes were hence 
thought to be tumor suppressor genes in gastric cancer, though their mechanisms 
were not clearly understood. Results using GIF and SNU16 cells however showed no 
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regulation of claudin-3, -4 and ZO-1 by RUNX3. RT-PCR results on SNU16 and AS 
SNU16 cells also did not show clear correlation between claudin-18 and -23 with 
RUNX3 (data not shown). It is possible that other than claudin-1, the expression of 
these proteins must be regulated by genes other than RUNX3.   
Claudin-1 knockout mice confirmed its important role in maintaining the 
barrier integrity in the epidermis (143). The up- and down-regulation of claudin-1 
expression have been well-documented in cancers. Decreased expression of claudin-1 
has been linked to the induction of tumor spheroids and recurrence status in breast 
cancer (170, 215). On the other hand, upregulation of claudin-1 expression 
contributes to colorectal carcinogenesis (164, 178, 216). Overexpression of claudin-1 
was also linked to the development of intestinal neoplasia (217). Two main signaling 
pathways have been described to regulate claudin-1 expression. The increased 
expression of claudin-1 in the β-catenin-Tcf / LEF signaling pathway was found to 
play a role in colorectal carcinogenesis (164). On the other hand, claudin-1 was 
identified as a direct downstream target gene of the Snail family of transcription 
factors, in the MAPK pathway. In human epithelial cells and invasive human breast 
tumors, high levels of Snail and Slug were correlated with low levels of claudin-1 
expression, indicating the Snail family transcription factors as repressors of claudin-1 
(188).  
  It is worth noting that a similar characteristic wrinkled skin appearance was 
observed in the Runx3 knockout mice (unpublished observation) as those observed in 
the claudin-1 knockout mice. The wrinkled skin appearance, a result from the loss of 
101 
 
epidermal barrier function, causes the claudin-1 knockout mice to die within 1 day of 
birth (143). 75% of Runx3 knockout mice died in the first day after birth, and none 
survived beyond 10 days. Though it was postulated that the Runx3 knockout mice 
may have died from starvation (23), the precise reason was not known. It could also 
be possible that lost of epidermal barrier function in the skin also contributed to the 
death of Runx3 knockout mice as those observed in claudin-1 knockout mice. These 
observations indicated a possible correlation between RUNX3 and claudin-1 
expression in the gastric epithelial cells which was worth investigating. 
Induction of claudin-1 expression by TGF-β is regulated at transcriptional 
level, as confirmed by RT-PCR and western analysis. The nuclear import of 
transcription factors is an essential factor in many signaling pathways to allow access 
of transcription factors to their target genes. Transcription factors such as the signal 
tranducers and activators of transcription (STAT) and Smads, require receptor-
mediated phosphorylation for conversion to their active state. The unstimulated forms 
of these proteins remain in the cytoplasm (218). Thus, transcription factors localized 
in the cytoplasm are thought to be in a basal, inactive state. TGF-β was recognized as 
the factor that stimulates nuclear translocation of RUNX3, thus switching the inactive 
form of RUNX3 to their active counterpart (97). This allows RUNX3 to physically 
bind to the promoter of their target genes, hence activating their expression, as 
observed in the case of claudin-1 induction upon stimulation by TGF-β.  
  It has been well documented that transcription factors like Snail and Slug act 
as repressors of claudin-1 expression in epithelial cells (188). Snail family genes are 
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transcription factors that play a central role in epithelial-mesenchymal transition 
(EMT), a process that occurs during cancer progression. During EMT, epithelial cells 
lose polarity. Though SNU16 cell line appeared to be unsuitable for the study of 
claudin-1 promoter assay in this study, it opens up new areas which could be explored 
to investigate possible connection between RUNX3 and Snail family transcription 
factor in the regulation of gastric epithelial cells. If their interaction is true, it would 
be interesting to observe how two antagonizing pathways could work together in the 
regulation and maintenance of epithelial cells.    
It has been postulated that TJ functions are altered during cancer progression 
due to loss of claudins expression. In non-tumorigenic epithelial tissues, TJ functions 
to regulate the flow of solutes between cell membranes, such as growth factors and 
cytokines. When TJ barrier functions are interrupted, growth factors and cytokines 
freely penetrate from the surrounding tissue, increasing paracellular flux of growth 
factors, which subsequently give rise to auto- and paracrine stimulation of 
tumorigenic epithelial cells. This lowering of diffusion barrier leads to an improved 
nutrient supply and adds to the selective advantage for developing tumor cells (191).  
This model could well explain the results in tumorigenicity assay using nude 
mice, whereby reintroduction of claudin-1 may have restored tight junction functions, 
thus reducing paracellular flux of growth factors, and minimizing tumorigenic 
epithelial cells and tumor formation. Collagen gel assay showed no reconstitution of 
cell polarity in GIF5 and GIF14 cells expressing exogenous claudin-1 (data not 
shown). Thus, the reduction of tumorigenicity could have worked through 
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mechanisms other than preserving the cell polarity, like the reconstitution of TJ 
barrier function. To confirm this, the use of electronmicroscopy technique (EM) may 






















CHAPTER 5   CONCLUSIONS AND FUTURE PERSPECTIVE  
 
For the first time, these findings supported the unsuspected role of RUNX3 as a tumor 
suppressor in gastric carcinogenesis through its direct regulation of tight junction 
protein, claudin-1. Claudin-1 also appears to be a tumor suppressor in the gastric 
system. It is also the first detailed report describing the regulation of claudin-1 by 
TGF-β signaling pathway. Therefore, a signaling cascade involving TGF-β, RUNX3 
and claudin-1 in the tumor suppression of gastric epithelial cells is proposed.  
 Based on the expression pattern of RUNX3 and claudin-1 in the human gastric 
cancer samples, RUNX3 was either not expressed or expressed but mislocalized in 
the cytoplasm as an inactive form in 71.2% (37/52) of the cases. RUNX3 negative 
cases were especially high (83%) in the differentiated type of gastric cancer. As such, 
RUNX3 is highly suitable to be used as a marker for diagnostic purposes. Claudin-1 
was either not expressed (32.7%) or expressed at a minimal level (38.5%) in the 
human gastric cancer samples. Although its expression pattern correlated with the 
expression of RUNX3, usage of claudin-1 alone as a diagnostic marker is deemed not 
sufficient.  
Unlike the staining pattern of RUNX3 which is easier to determine (in nucleus 
or cytoplasm), the claudin-1 expression level in the positive cases (high or low) may 
be harder to be determined by eye, unless a fixed parameter is utilized through the use 
of a software. Even then, a positive reference or normal tissue counterpart need to be 
tested alongside each time a sample is to be tested for claudin-1 expression. As 
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availability of normal tissue counterpart may not be feasible all the time, plus the fact 
that the expression level of claudin-1 may vary in between tissue samples, 
comparison of claudin-1 expression level in each patient tissue can become daunting 
and less accurate. Thus, it will be more meaningful to carry out RUNX3 and claudin-
1 expression at the same time for diagnosis purposes. With this, markers with better 
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VECTOR FOR HOMOLOGOUS RECOMBINATION, AND THE GENE 













FULL LENGTH SEQUENCE OF hCLAUDIN-1 PROMOTER (1530 bp) 



























































Note: The SV40 promoter was removed at the Bgl II and Hind III restriction sites and 







Human RUNX3 cDNA  









































FULL LENGTH SEQUENCE OF mCLAUDIN-1  



































FULL LENGTH SEQUENCE OF hCLAUDIN-1  
OPEN READING FRAME (636 bp) 
 
 
atggccaacgcggggctgcagctgttgggcttcattctcgccttcctgggatggatc
ggcgccatcgtcagcactgccctgccccagtggaggatttactcctatgccggcgac
aacatcgtgaccgcccaggccatgtacgaggggctgtggatgtcctgcgtgtcgcag
agcaccgggcagatccagtgcaaagtctttgactccttgctgaatctgagcagcaca
ttgcaagcaacccgtgccttgatggtggttggcatcctcctgggagtgatagcaatc
tttgtggccaccgttggcatgaagtgtatgaagtgcttggaagacgatgaggtgcag
aagatgaggatggctgtcattgggggtgcgatatttcttcttgcaggtctggctatt
ttagttgccacagcatggtatggcaatagaatcgttcaagaattctatgaccctatg
accccagtcaatgccaggtacgaatttggtcaggctctcttcactggctgggctgct
gcttctctctgccttctgggaggtgccctactttgctgttcctgtccccgaaaaaca
acctcttacccaacaccaaggccctatccaaaacctgcaccttccagcgggaaagac
tacgtgtga 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
